Characterization	O
of	O
a	O
CD43/leukosialin	B-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-lymphoblastoid	I-cell_type
cells	I-cell_type
.	O

The	O
monoclonal	B-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
J393	B-protein
induces	O
apoptosis	O
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
.	O

NH2	B-protein
-terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140-kDa	B-protein
surface	I-protein
antigen	I-protein
for	O
mAb	B-protein
J393	I-protein
as	O
CD43/leukosialin	B-protein
,	O
the	O
major	O
sialoglycoprotein	B-protein
of	O
leukocytes	B-cell_type
.	O

While	O
Jurkat	B-cell_line
cells	I-cell_line
co-expressed	O
two	O
discrete	O
cell-surface	B-protein
isoforms	I-protein
of	O
CD43	B-protein
,	O
recognized	O
by	O
mAb	B-protein
J393	I-protein
and	O
mAb	B-protein
G10-2	I-protein
,	O
respectively	O
,	O
only	O
J393/CD43	B-protein
signaled	O
apoptosis	O
.	O

J393/CD43	B-protein
was	O
found	O
to	O
be	O
hyposialylated	O
,	O
bearing	O
predominantly	O
O-linked	O
monosaccharide	O
glycans	O
,	O
whereas	O
G10-2/CD43	B-protein
bore	O
complex	O
sialylated	O
tetra-	O
and	O
hexasaccharide	O
chains	O
.	O

Treatment	O
with	O
soluble	O
,	O
bivalent	O
mAb	B-protein
J393	I-protein
killed	O
25-50	O
%	O
of	O
the	O
cell	B-cell_line
population	I-cell_line
,	O
while	O
concomitant	O
engagement	O
of	O
either	O
the	O
CD3.TcR	B-protein
complex	I-protein
or	O
the	O
integrins	B-protein
CD18	B-protein
and	O
CD29	B-protein
significantly	O
potentiated	O
this	O
effect	O
.	O

Treatment	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
mAb	B-protein
J393	I-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	B-protein
substrates	I-protein
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	B-protein
receptor	I-protein
costimulation	O
.	O

Tyrosine	B-protein
kinase	I-protein
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393/CD43	B-protein
-mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	B-protein
phosphatase	I-protein
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium-IV	O
enhanced	O
cell	O
death	O
.	O

Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393/	O
CD43	B-protein
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	B-protein
regulatory	I-protein
protein	I-protein
NF-kappaB	B-protein
and	O
proteins	O
binding	O
the	O
interferon-inducible	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

Since	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
express	O
cryptic	B-protein
epitopes	I-protein
for	O
mAb	B-protein
J393	I-protein
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43	B-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-cell	I-cell_type
lineages	I-cell_type
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1996	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

271	NULL
,	NULL
No	NULL
.	NULL

44	NULL
,	NULL
Issue	NULL
of	NULL
November	NULL
1	NULL
,	NULL
pp	NULL
.	NULL

27686-27695	NULL
,	NULL
1996	NULL
Printed	NULL
in	NULL
U.S.A	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
CD43/Leukosialin-mediated	NULL
Pathway	NULL
for	NULL
Inducing	NULL
Apoptosis	NULL
in	NULL
Human	NULL
T-Lymphoblastoid	NULL
Cells*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
February	NULL
8	NULL
,	NULL
1996	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
August	NULL
16	NULL
,	NULL
1996	NULL
)	NULL
T.	NULL
Joseph	NULL
Brown	NULL
,	NULL
Walt	NULL
W.	NULL
Shuford	NULL
,	NULL
Wei-Chun	NULL
Wang	NULL
,	NULL
Steven	NULL
G.	NULL
Nadler	NULL
,	NULL
Tina	NULL
S.	NULL
Bailey	NULL
,	NULL
Hans	NULL
Marquardt	NULL
,	NULL
and	NULL
Robert	NULL
S.	NULL
Mittlert	NULL
From	NULL
the	NULL
Bristol-Myers	NULL
Squibb	NULL
Pharmaceutical	NULL
Research	NULL
Institute	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
98121	NULL
The	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
J393	NULL
induces	NULL
apoptosis	NULL
in	NULL
Jurkat	NULL
T-cells	NULL
.	NULL

NH-terminal	NULL
amino	NULL
acid	NULL
sequence	NULL
analysis	NULL
identified	NULL
the	NULL
140-kDa	NULL
surface	NULL
antigen	NULL
for	NULL
mAb	NULL
J393	NULL
as	NULL
CD43/leukosialin	NULL
,	NULL
the	NULL
major	NULL
sialoglycoprotein	NULL
of	NULL
leukocytes	NULL
.	NULL

While	NULL
Jurkat	NULL
cells	NULL
co-expressed	NULL
two	NULL
discrete	NULL
cell-surface	NULL
isoforms	NULL
of	NULL
CD43	NULL
,	NULL
recognized	NULL
by	NULL
mAb	NULL
J393	NULL
and	NULL
mAb	NULL
G10-2	NULL
,	NULL
respectively	NULL
,	NULL
only	NULL
J398/CD48	NULL
signaled	NULL
apoptosis	NULL
.	NULL

J393/CD43	NULL
was	NULL
found	NULL
to	NULL
be	NULL
hyposialylated	NULL
,	NULL
bearing	NULL
predominantly	NULL
O-linked	NULL
monosaccharide	NULL
gly-cans	NULL
,	NULL
whereas	NULL
G10-2/CD43	NULL
bore	NULL
complex	NULL
sialylated	NULL
tetra-and	NULL
hexasaccharide	NULL
chains	NULL
.	NULL

Treatment	NULL
with	NULL
soluble	NULL
,	NULL
bivalent	NULL
mAb	NULL
J393	NULL
killed	NULL
25-50	NULL
%	NULL
of	NULL
the	NULL
cell	NULL
population	NULL
,	NULL
while	NULL
concomitant	NULL
engagement	NULL
of	NULL
either	NULL
the	NULL
CD3-TcR	NULL
complex	NULL
or	NULL
the	NULL
integrins	NULL
CD18	NULL
and	NULL
CD29	NULL
significantly	NULL
potentiated	NULL
this	NULL
effect	NULL
.	NULL

Treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
mAb	NULL
J393	NULL
induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
specific	NULL
protein	NULL
substrates	NULL
that	NULL
underwent	NULL
hyperphosphorylation	NULL
upon	NULL
antigen	NULL
receptor	NULL
costimulation	NULL
.	NULL

Tyrosine	NULL
kinase	NULL
inhibition	NULL
by	NULL
herbimycin	NULL
A	NULL
diminished	NULL
J393/CD43-mediated	NULL
apoptosis	NULL
,	NULL
whereas	NULL
inhibition	NULL
of	NULL
phosphotyrosine	NULL
phosphatase	NULL
activity	NULL
by	NULL
bis	NULL
(	NULL
maltolato	NULL
)	NULL
oxovanadium-IV	NULL
enhanced	NULL
cell	NULL
death	NULL
.	NULL

Signal	NULL
transduction	NULL
through	NULL
tyrosine	NULL
kinase	NULL
activation	NULL
may	NULL
lead	NULL
to	NULL
altered	NULL
gene	NULL
expression	NULL
,	NULL
as	NULL
J393/CD43	NULL
ligation	NULL
prompted	NULL
decreases	NULL
in	NULL
the	NULL
nuclear	NULL
localization	NULL
of	NULL
the	NULL
transcriptional	NULL
regulatory	NULL
protein	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
proteins	NULL
binding	NULL
the	NULL
interferon-inducible	NULL
regulatory	NULL
element	NULL
.	NULL

Since	NULL
peripheral	NULL
blood	NULL
T-lymphocytes	NULL
express	NULL
cryptic	NULL
epitopes	NULL
for	NULL
mAb	NULL
J393	NULL
,	NULL
these	NULL
findings	NULL
demonstrate	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
tightly	NULL
regulated	NULL
CD43-mediated	NULL
pathway	NULL
for	NULL
inducing	NULL
apoptosis	NULL
in	NULL
human	NULL
T-cell	NULL
lineages	NULL
.	NULL

In	NULL
T-lymphocytes	NULL
CD43/leukosialin	NULL
,	NULL
the	NULL
major	NULL
sialoglycoprotein	NULL
of	NULL
leukocytes	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
,	NULL
is	NULL
thought	NULL
to	NULL
serve	NULL
a	NULL
dual	NULL
role	NULL
in	NULL
regulating	NULL
cellular	NULL
immune	NULL
responses	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
repulsive	NULL
effect	NULL
of	NULL
its	NULL
high	NULL
numbers	NULL
of	NULL
O-linked	NULL
negatively	NULL
charged	NULL
sialic	NULL
acid	NULL
sugar	NULL
residues	NULL
,	NULL
CD43	NULL
acts	NULL
as	NULL
a	NULL
``	NULL
barrier	NULL
molecule	NULL
``	NULL
by	NULL
limiting	NULL
cell-cell/cell-ligand	NULL
interactions	NULL
(	NULL
3-7	NULL
)	NULL
,	NULL
a	NULL
property	NULL
that	NULL
may	NULL
negatively	NULL
regulate	NULL
T-cell	NULL
activation	NULL
(	NULL
8	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
engagement	NULL
of	NULL
CD43	NULL
by	NULL
monoclonal	NULL
antibodies	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
costimulatory	NULL
activity	NULL
in	NULL
T-cells	NULL
by	NULL
a	NULL
mechanism	NULL
analogous	NULL
to	NULL
a	NULL
classic	NULL
ligand-receptor	NULL
interaction	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

Alterations	NULL
in	NULL
O-glycan	NULL
structure	NULL
and	NULL
function	NULL
of	NULL
CD43	NULL
reportedly	NULL
occur	NULL
in	NULL
the	NULL
immunodeficiency	NULL
disorders	NULL
Wiskott-Aldrich	NULL
syndrome	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
and	NULL
AIDS	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
as	NULL
well	NULL
as	NULL
in	NULL
graft	NULL
versus	NULL
host	NULL
disease	NULL
(	NULL
16	NULL
)	NULL
,	NULL
acute	NULL
lymphocytic	NULL
leukemia	NULL
(	NULL
17	NULL
)	NULL
,	NULL
and	NULL
permanent	NULL
*	NULL
The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1784	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

$	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
3005	NULL
First	NULL
Ave.	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
98121	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
206-727-8541	NULL
;	NULL
Fax	NULL
:	NULL
206-727-3600.	NULL
mixed-field	NULL
polyagglutinability	NULL
or	NULL
Tn	NULL
antigen	NULL
syndrome	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
molecular	NULL
structure	NULL
of	NULL
human	NULL
CD43	NULL
is	NULL
mucin-like	NULL
,	NULL
consisting	NULL
of	NULL
an	NULL
extended	NULL
rod-shaped	NULL
extracellular	NULL
portion	NULL
bearing	NULL
approximately	NULL
80	NULL
sialylated	NULL
O-glycan	NULL
sites	NULL
and	NULL
a	NULL
single	NULL
N-glycan	NULL
site	NULL
,	NULL
a	NULL
highly	NULL
conserved	NULL
transmembrane	NULL
region	NULL
,	NULL
and	NULL
a	NULL
long	NULL
cytoplasmic	NULL
domain	NULL
bearing	NULL
potential	NULL
serine/threonine	NULL
phosphorylation	NULL
sites	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
exon/intron	NULL
arrangement	NULL
within	NULL
its	NULL
gene	NULL
,	NULL
the	NULL
observed	NULL
molecular	NULL
heterogeneity	NULL
of	NULL
CD43	NULL
in	NULL
both	NULL
mice	NULL
and	NULL
man	NULL
is	NULL
thought	NULL
to	NULL
reflect	NULL
differential	NULL
post-translational	NULL
modifications	NULL
of	NULL
a	NULL
single	NULL
gene	NULL
product	NULL
(	NULL
20-22	NULL
)	NULL
.	NULL

Linear	NULL
protein	NULL
epitopes	NULL
in	NULL
the	NULL
native	NULL
structure	NULL
of	NULL
CD43	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
modified	NULL
by	NULL
glycosylation	NULL
(	NULL
23	NULL
)	NULL
,	NULL
allowing	NULL
for	NULL
the	NULL
development	NULL
of	NULL
isoform-specific	NULL
antibodies	NULL
(	NULL
9	NULL
,	NULL
11	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Following	NULL
T-cell	NULL
activation	NULL
,	NULL
the	NULL
O-linked	NULL
oligosaccharides	NULL
of	NULL
CD43	NULL
change	NULL
from	NULL
tetrasaccharides	NULL
(	NULL
mAb'*	NULL
G10-2	NULL
reactive	NULL
)	NULL
to	NULL
more	NULL
complex	NULL
hexasaccharides	NULL
(	NULL
mAb	NULL
T-305	NULL
reactive	NULL
)	NULL
due	NULL
to	NULL
the	NULL
activation-induced	NULL
expression	NULL
of	NULL
core	NULL
2	NULL
B1-6	NULL
N-acetylglu-cosaminyltransferase	NULL
(	NULL
17	NULL
,	NULL
25	NULL
)	NULL
.	NULL

This	NULL
change	NULL
in	NULL
oligosaccharide	NULL
structure	NULL
results	NULL
in	NULL
a	NULL
shift	NULL
from	NULL
115	NULL
to	NULL
140	NULL
kDa	NULL
(	NULL
9	NULL
,	NULL
17	NULL
,	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

There	NULL
is	NULL
little	NULL
information	NULL
correlating	NULL
heterogeneity	NULL
in	NULL
oligosaccharide	NULL
structure	NULL
with	NULL
ligand	NULL
specificity	NULL
or	NULL
the	NULL
signal	NULL
trans-ducing	NULL
properties	NULL
of	NULL
CD43	NULL
.	NULL

In	NULL
the	NULL
thymus	NULL
,	NULL
thymocyte-thymic	NULL
epithelial	NULL
cell	NULL
interactions	NULL
correlate	NULL
with	NULL
the	NULL
preferential	NULL
binding	NULL
of	NULL
galectin-1	NULL
to	NULL
the	NULL
mAb	NULL
T-305/CD43	NULL
isoform	NULL
expressed	NULL
in	NULL
immature	NULL
,	NULL
cortical	NULL
thymocytes	NULL
(	NULL
27	NULL
)	NULL
.	NULL

In	NULL
mature	NULL
T-cells	NULL
the	NULL
binding	NULL
of	NULL
anti-CD43	NULL
antibodies	NULL
,	NULL
thought	NULL
to	NULL
mimic	NULL
natural	NULL
ligands	NULL
,	NULL
results	NULL
in	NULL
CD28-independent	NULL
costimulatory	NULL
activity	NULL
(	NULL
11	NULL
,	NULL
28-31	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
L10	NULL
antibody	NULL
directed	NULL
against	NULL
a	NULL
neuraminidase-resistant	NULL
epitope	NULL
of	NULL
CD43	NULL
is	NULL
a	NULL
strong	NULL
inducer	NULL
of	NULL
T-cell	NULL
proliferation	NULL
,	NULL
whereas	NULL
the	NULL
B1B6	NULL
antibody	NULL
directed	NULL
against	NULL
a	NULL
neuraminidase-sensitive	NULL
epitope	NULL
is	NULL
only	NULL
weakly	NULL
mitogenic	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Immunoprecipitations	NULL
from	NULL
T-lymphoblastoid	NULL
cell	NULL
lysates	NULL
have	NULL
found	NULL
CD43	NULL
to	NULL
be	NULL
associated	NULL
with	NULL
CD3/TcR	NULL
and	NULL
p56*	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
(	NULL
11	NULL
)	NULL
,	NULL
providing	NULL
both	NULL
physical	NULL
and	NULL
functional	NULL
evidence	NULL
for	NULL
a	NULL
role	NULL
for	NULL
CD43	NULL
in	NULL
signal	NULL
transduction	NULL
.	NULL

The	NULL
anti-CD43	NULL
antibody	NULL
,	NULL
mAb	NULL
MEM-59	NULL
,	NULL
which	NULL
is	NULL
costimulatory	NULL
in	NULL
T-lymphocytes	NULL
has	NULL
recently	NULL
been	NULL
reported	NULL
to	NULL
induce	NULL
programmed	NULL
cell	NULL
death	NULL
or	NULL
apoptosis	NULL
in	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Clearly	NULL
,	NULL
CD43-mediated	NULL
responses	NULL
can	NULL
differ	NULL
significantly	NULL
depending	NULL
on	NULL
the	NULL
cell	NULL
type	NULL
and	NULL
the	NULL
isoform	NULL
being	NULL
expressed	NULL
.	NULL

While	NULL
aberrant	NULL
isoforms	NULL
of	NULL
CD43	NULL
have	NULL
been	NULL
associated	NULL
with	NULL
immuno-deficiencies	NULL
resulting	NULL
in	NULL
lymphopenia	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
,	NULL
there	NULL
has	NULL
been	NULL
no	NULL
direct	NULL
evidence	NULL
linking	NULL
CD43-mediated	NULL
apoptosis	NULL
with	NULL
T-cell	NULL
depletion	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
TeR	NULL
,	NULL
T-cell	NULL
receptor	NULL
;	NULL
FACS	NULL
,	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
;	NULL
FITC	NULL
,	NULL
fluorescein	NULL
isothiocyanate	NULL
;	NULL
PE	NULL
,	NULL
phycoerythrin	NULL
;	NULL
PI	NULL
,	NULL
propidium	NULL
iodide	NULL
;	NULL
PHA	NULL
,	NULL
phyto-hemagglutinin	NULL
;	NULL
BMLOV	NULL
,	NULL
bis	NULL
(	NULL
maltolato	NULL
)	NULL
oxovanadium-IV	NULL
;	NULL
NF	NULL
,	NULL
B	NULL
,	NULL
nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
;	NULL
MOPS	NULL
,	NULL
3-	NULL
[	NULL
N-morpholino|propanesulfonic	NULL
acid	NULL
;	NULL
Tricine	NULL
,	NULL
N-	NULL
[	NULL
2-hydroxy-1,1-bis	NULL
(	NULL
hydroxymethyl	NULL
)	NULL
ethyllglycine	NULL
;	NULL
PTPase	NULL
,	NULL
phosphotyrosine	NULL
phosphatase	NULL
;	NULL
IRE	NULL
,	NULL
interferon-inducible	NULL
regulatory	NULL
element	NULL
.	NULL

27686	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Induction	NULL
of	NULL
Apoptosis	NULL
in	NULL
T-cells	NULL
by	NULL
Anti-CD43	NULL
mAb	NULL
Here	NULL
we	NULL
report	NULL
the	NULL
biochemical	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
an	NULL
anti-CD43	NULL
mAb	NULL
designated	NULL
J393	NULL
that	NULL
recognizes	NULL
a	NULL
unique	NULL
,	NULL
alternatively	NULL
glycosylated	NULL
isoform	NULL
of	NULL
CD43	NULL
expressed	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
the	NULL
human	NULL
T-lymphoblastoid	NULL
cell	NULL
line	NULL
,	NULL
Jurkat	NULL
.	NULL

Treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
mAb	NULL
J393	NULL
induces	NULL
apoptosis	NULL
in	NULL
a	NULL
CD43	NULL
isoform-specific	NULL
manner	NULL
.	NULL

The	NULL
level	NULL
of	NULL
apoptosis	NULL
may	NULL
be	NULL
enhanced	NULL
by	NULL
concomitant	NULL
engagement	NULL
of	NULL
the	NULL
TcR	NULL
or	NULL
integrin	NULL
molecules	NULL
.	NULL

Moreover	NULL
,	NULL
an	NULL
isoform	NULL
of	NULL
CD43	NULL
is	NULL
detected	NULL
in	NULL
peripheral	NULL
blood	NULL
T-lymphocytes	NULL
bearing	NULL
a	NULL
cryptic	NULL
epitope	NULL
for	NULL
mAb	NULL
J393	NULL
.	NULL

These	NULL
results	NULL
describe	NULL
a	NULL
potentially	NULL
novel	NULL
mechanism	NULL
for	NULL
T-cell	NULL
lineage	NULL
depletion	NULL
involving	NULL
the	NULL
regulated	NULL
expression	NULL
of	NULL
specific	NULL
isoforms	NULL
of	NULL
CD43	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Cells	NULL
and	NULL
Reagents-All	NULL
cell	NULL
lines	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
Hyclone	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
and	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
100	NULL
mg/ml	NULL
streptomycin	NULL
unless	NULL
otherwise	NULL
stated	NULL
.	NULL

The	NULL
BMS-2	NULL
subclone	NULL
of	NULL
Jurkat	NULL
cells	NULL
and	NULL
the	NULL
HPB-F6	NULL
subclone	NULL
of	NULL
HPB-ALL	NULL
cells	NULL
were	NULL
developed	NULL
at	NULL
Bristol-Myers	NULL
Squibb	NULL
,	NULL
and	NULL
the	NULL
anti-CD43	NULL
mAb	NULL
G10-2	NULL
and	NULL
mAb	NULL
G19-1	NULL
,	NULL
anti-CD3	NULL
mAb	NULL
G19-4	NULL
,	NULL
and	NULL
G19-4-sFv	NULL
fusion	NULL
protein	NULL
(	NULL
85	NULL
)	NULL
and	NULL
anti-CD18	NULL
(	NULL
B2-integrin	NULL
)	NULL
mAb	NULL
60.3	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Jeffrey	NULL
Ledbetter	NULL
(	NULL
Bristol-Myers	NULL
Squibb	NULL
PRI	NULL
(	NULL
BMSPRI	NULL
)	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
.	NULL

The	NULL
anti-MHC	NULL
class	NULL
I	NULL
mAb	NULL
W6/82	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
ATCC	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
anti-CD28	NULL
mAb	NULL
2612	NULL
was	NULL
produced	NULL
by	NULL
Dr.	NULL
Robert	NULL
Mittler	NULL
(	NULL
BMSPRI	NULL
)	NULL
.	NULL

The	NULL
anti-CD48	NULL
mAb	NULL
T-805	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
Minoru	NULL
Fukuda	NULL
(	NULL
La	NULL
Jolla	NULL
Cancer	NULL
Research	NULL
Foundation	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Anti-CD49d	NULL
(	NULL
a4-integrin	NULL
)	NULL
mAb	NULL
P4C2	NULL
and	NULL
anti-CD29	NULL
(	NULL
l-integrin	NULL
)	NULL
mAb	NULL
P4C1O	NULL
were	NULL
provided	NULL
as	NULL
ascites	NULL
preparations	NULL
by	NULL
Dr.	NULL
Paul	NULL
Gladstone	NULL
(	NULL
BMSPRI	NULL
)	NULL
.	NULL

The	NULL
phosphotyrosine	NULL
phosphatase	NULL
inhibitor	NULL
,	NULL
bis-	NULL
(	NULL
maltolato	NULL
)	NULL
oxovanadium-IV	NULL
(	NULL
BM-LOV	NULL
)	NULL
,	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Gary	NULL
Schieven	NULL
(	NULL
BMSPRI	NULL
)	NULL
.	NULL

Herbimycin	NULL
A	NULL
was	NULL
purchased	NULL
from	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc	NULL
.	NULL

The	NULL
anti-CD95/Fas	NULL
monoclonal	NULL
antibody	NULL
(	NULL
IgM	NULL
isotype	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
and	NULL
the	NULL
CD95/Fas	NULL
neutralizing	NULL
mAb	NULL
7B4	NULL
was	NULL
purchased	NULL
from	NULL
Immunotech	NULL
Inc.	NULL
(	NULL
Westbrook	NULL
,	NULL
ME	NULL
)	NULL
.	NULL

All	NULL
glyco-lytic	NULL
enzymes	NULL
except	NULL
Vibrio	NULL
cholerae	NULL
neuraminidase	NULL
(	NULL
Calbiochem	NULL
)	NULL
and	NULL
Clostridium	NULL
perfringens	NULL
neuraminidase	NULL
(	NULL
Sigma	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Oxford	NULL
GlycoSystems	NULL
Inc.	NULL
(	NULL
Rosedale	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Nonspecific	NULL
protease	NULL
XIV	NULL
from	NULL
Streptomyces	NULL
griseus	NULL
(	NULL
Pronase	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

Protease	NULL
inhibitors	NULL
were	NULL
obtained	NULL
from	NULL
Boehringer	NULL
Mannheim	NULL
.	NULL

FITC-conjugated	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
was	NULL
purchased	NULL
from	NULL
TAGO	NULL
,	NULL
Inc.	NULL
(	NULL
Burl-ingame	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

PE-	NULL
and	NULL
FITC-conjugated	NULL
streptavidin	NULL
and	NULL
propidium	NULL
iodide	NULL
were	NULL
purchased	NULL
from	NULL
Molecular	NULL
Probes	NULL
,	NULL
Inc.	NULL
(	NULL
Eugene	NULL
,	NULL
OR	NULL
)	NULL
.	NULL

Cytofluorometric	NULL
Analysis	NULL
of	NULL
CD43	NULL
Expression	NULL
and	NULL
CD43-induced	NULL
Apoptosis-Both	NULL
the	NULL
level	NULL
of	NULL
cell-surface	NULL
expression	NULL
of	NULL
CD43	NULL
and	NULL
the	NULL
level	NULL
of	NULL
apoptosis	NULL
(	NULL
cell	NULL
death	NULL
)	NULL
were	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
FACS	NULL
)	NULL
using	NULL
a	NULL
FACStar	NULL
fluorescence	NULL
activated	NULL
cell	NULL
sorter	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
controlled	NULL
by	NULL
the	NULL
Cicero	NULL
automated	NULL
data	NULL
acquisition	NULL
and	NULL
analysis	NULL
system	NULL
(	NULL
Cytomation	NULL
,	NULL
Fort	NULL
Collins	NULL
,	NULL
CO	NULL
)	NULL
.	NULL

Data	NULL
were	NULL
collected	NULL
for	NULL
1	NULL
X	NULL
104	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
phenotyped	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
86	NULL
)	NULL
.	NULL

Apoptosis	NULL
within	NULL
a	NULL
culture	NULL
was	NULL
determined	NULL
by	NULL
incubating	NULL
cell	NULL
samples	NULL
with	NULL
10	NULL
ug/ml	NULL
propidium	NULL
iodide	NULL
(	NULL
PTI	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
prior	NULL
to	NULL
analysis	NULL
.	NULL

Dead	NULL
cells	NULL
exhibiting	NULL
size	NULL
reduction	NULL
and	NULL
PI	NULL
fluorescence	NULL
were	NULL
electronically	NULL
gated	NULL
into	NULL
quadrants	NULL
1-8	NULL
and	NULL
counted	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
total	NULL
cell	NULL
population	NULL
.	NULL

FACS	NULL
analysis	NULL
of	NULL
DNA	NULL
fragmentation	NULL
was	NULL
carried	NULL
out	NULL
after	NULL
incubating	NULL
cell	NULL
samples	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
0.08	NULL
%	NULL
sodium	NULL
citrate	NULL
,	NULL
0.01	NULL
%	NULL
Triton	NULL
X-100	NULL
)	NULL
containing	NULL
50	NULL
ug/ml	NULL
PI	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
by	NULL
forward	NULL
light	NULL
scatter	NULL
versus	NULL
fluorescence	NULL
to	NULL
generate	NULL
a	NULL
histogram	NULL
representing	NULL
the	NULL
size	NULL
and	NULL
relative	NULL
amount	NULL
of	NULL
fragmented	NULL
DNA	NULL
.	NULL

Purification	NULL
of	NULL
the	NULL
mAb	NULL
J393	NULL
Antigen-The	NULL
antigen	NULL
for	NULL
mAb	NULL
J898	NULL
was	NULL
purified	NULL
by	NULL
affinity	NULL
chromatography	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
a	NULL
high-expresser	NULL
subclone	NULL
of	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
,	NULL
BMS-2	NULL
.	NULL

The	NULL
affinity	NULL
column	NULL
was	NULL
prepared	NULL
by	NULL
covalently	NULL
attaching	NULL
purified	NULL
mAb	NULL
J398	NULL
to	NULL
GammaBind	NULL
Plus	NULL
protein	NULL
G-Sepharose	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
Inc.	NULL
)	NULL
using	NULL
maleimide	NULL
as	NULL
the	NULL
cross-linking	NULL
reagent	NULL
.	NULL

Non-covalently	NULL
attached	NULL
antibody	NULL
was	NULL
removed	NULL
by	NULL
alternating	NULL
rinses	NULL
in	NULL
pH	NULL
4.0	NULL
and	NULL
pH	NULL
9.0	NULL
Tris	NULL
buffers	NULL
.	NULL

BMS-2	NULL
cell	NULL
pellets	NULL
were	NULL
solubilized	NULL
at	NULL
4	NULL
°C	NULL
in	NULL
Nonidet	NULL
P-40	NULL
lysis	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
140	NULL
mM	NULL
NaCl	NULL
,	NULL
20	NULL
mM	NULL
Tris	NULL
,	NULL
10	NULL
mM	NULL
EDTA	NULL
)	NULL
containing	NULL
protease	NULL
inhibitors	NULL
(	NULL
PMSF	NULL
,	NULL
leupeptin	NULL
,	NULL
soybean	NULL
trypsin	NULL
inhibitor	NULL
,	NULL
pepstatin	NULL
,	NULL
and	NULL
antipain	NULL
)	NULL
and	NULL
the	NULL
protein	NULL
concentration	NULL
adjusted	NULL
to	NULL
2	NULL
mg/ml	NULL
.	NULL

The	NULL
lysate	NULL
was	NULL
clarified	NULL
by	NULL
centrifugation	NULL
at	NULL
100,00	NULL
%	NULL
g	NULL
for	NULL
90	NULL
min	NULL
and	NULL
consecutively	NULL
passaged	NULL
through	NULL
a	NULL
15-ml	NULL
GammaBind	NULL
Plus	NULL
column	NULL
,	NULL
a	NULL
10-ml	NULL
GammaBind	NULL
Plus	NULL
column	NULL
with	NULL
control	NULL
mAb	NULL
P3X	NULL
at-tached	NULL
,	NULL
and	NULL
a	NULL
2-ml	NULL
GammaBind	NULL
Plus	NULL
column	NULL
with	NULL
mAb	NULL
J398	NULL
attached	NULL
.	NULL

217687	NULL
The	NULL
mAb	NULL
J8938	NULL
affinity	NULL
column	NULL
was	NULL
flushed	NULL
with	NULL
lysis	NULL
buffer	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
followed	NULL
by	NULL
another	NULL
rinse	NULL
with	NULL
lysis	NULL
buffer	NULL
containing	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
0.1	NULL
%	NULL
deoxycholate	NULL
,	NULL
and	NULL
20	NULL
mM	NULL
MOPS	NULL
.	NULL

Antigen	NULL
was	NULL
eluted	NULL
using	NULL
glycine	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
glycine	NULL
,	NULL
0.1	NULL
%	NULL
deoxycholate	NULL
,	NULL
pH	NULL
11.5	NULL
)	NULL
and	NULL
the	NULL
pH	NULL
adjusted	NULL
to	NULL
8.0	NULL
with	NULL
2	NULL
M	NULL
Tris	NULL
.	NULL

The	NULL
antigen	NULL
preparation	NULL
was	NULL
dialyzed/	NULL
concentrated	NULL
by	NULL
filtration	NULL
using	NULL
10	NULL
mM	NULL
Tris	NULL
buffer	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
containing	NULL
0.1	NULL
%	NULL
deoxycholate	NULL
prior	NULL
to	NULL
amino	NULL
acid	NULL
sequence	NULL
analysis	NULL
.	NULL

Protein	NULL
Sequencing-The	NULL
affinity-purified	NULL
antigen	NULL
for	NULL
mAb	NULL
J898	NULL
was	NULL
prepared	NULL
for	NULL
protein	NULL
sequencing	NULL
by	NULL
subjecting	NULL
the	NULL
sample	NULL
to	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
using	NULL
a	NULL
SDS-Tricine	NULL
buffer	NULL
system	NULL
(	NULL
Bio-Rad	NULL
)	NULL
on	NULL
a	NULL
minigel	NULL
apparatus	NULL
(	NULL
80	NULL
X	NULL
80	NULL
X	NULL
0.5	NULL
mm	NULL
)	NULL
with	NULL
a	NULL
10	NULL
%	NULL
acrylamide	NULL
resolving	NULL
gel	NULL
and	NULL
a	NULL
4	NULL
%	NULL
acrylamide	NULL
stacking	NULL
layer	NULL
run	NULL
under	NULL
reducing	NULL
conditions	NULL
.	NULL

The	NULL
separated	NULL
proteins	NULL
were	NULL
then	NULL
electroblotted	NULL
(	NULL
87	NULL
)	NULL
onto	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
(	NULL
Immobilon-P	NULL
,	NULL
Millipore	NULL
Corp.	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
and	NULL
the	NULL
location	NULL
of	NULL
the	NULL
mAb	NULL
J898	NULL
antigen	NULL
was	NULL
confirmed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

The	NULL
Coomassie	NULL
Brilliant	NULL
Blue	NULL
stainable	NULL
band	NULL
of	NULL
protein	NULL
corresponding	NULL
to	NULL
the	NULL
140-kDa	NULL
mAb	NULL
J898	NULL
antigen	NULL
was	NULL
subjected	NULL
to	NULL
NH	NULL
,	NULL
-terminal	NULL
amino	NULL
acid	NULL
sequence	NULL
analysis	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Automated	NULL
sequence	NULL
analysis	NULL
was	NULL
performed	NULL
in	NULL
a	NULL
pulsed-liquid	NULL
protein	NULL
sequencer	NULL
(	NULL
model	NULL
476A	NULL
,	NULL
Applied	NULL
Biosystems	NULL
,	NULL
Inc.	NULL
)	NULL
using	NULL
manufacturer-released	NULL
cycle	NULL
programs	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
89	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
Oligosaccharides	NULL
Attached	NULL
to	NULL
CD43-Cells	NULL
were	NULL
metabol-ically	NULL
labeled	NULL
with	NULL
[	NULL
*Hglucosamine	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
glucose-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
dialyzed	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
2	NULL
%	NULL
standard	NULL
medium	NULL
.	NULL

Cells	NULL
were	NULL
labeled	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
with	NULL
20	NULL
uCi/ml	NULL
[	NULL
®H	NULL
]	NULL
glu-cosamine	NULL
(	NULL
40	NULL
Ci/mmol	NULL
;	NULL
DuPont	NULL
NEN	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
harvested	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
before	NULL
disruption	NULL
in	NULL
ice-cold	NULL
lysis	NULL
buffer	NULL
(	NULL
PBS	NULL
containing	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
and	NULL
1	NULL
mg/ml	NULL
each	NULL
of	NULL
leupep-tin	NULL
and	NULL
aprotinin	NULL
)	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
clarified	NULL
by	NULL
high	NULL
speed	NULL
centrifugation	NULL
and	NULL
the	NULL
supernatants	NULL
collected	NULL
.	NULL

Radiolabeled	NULL
CD43	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
these	NULL
supernatants	NULL
with	NULL
10	NULL
ug/ml	NULL
anti-CD43	NULL
mAb	NULL
and	NULL
the	NULL
resulting	NULL
immune-complex	NULL
recovered	NULL
by	NULL
binding	NULL
to	NULL
protein	NULL
A-Sepharose	NULL
.	NULL

O-Linked	NULL
oligosaccharides	NULL
were	NULL
released	NULL
from	NULL
the	NULL
immunoprecipitates	NULL
by	NULL
B-elimination	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
41	NULL
)	NULL
,	NULL
desalted	NULL
on	NULL
a	NULL
Sephadex	NULL
G-10	NULL
column	NULL
,	NULL
dried	NULL
,	NULL
taken	NULL
up	NULL
in	NULL
water	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
high	NULL
performance	NULL
liquid	NULL
chromatography	NULL
on	NULL
a	NULL
column	NULL
(	NULL
0.4	NULL
X	NULL
30	NULL
cm	NULL
)	NULL
of	NULL
amino-bonded	NULL
silica	NULL
(	NULL
AX-10	NULL
,	NULL
Varian	NULL
)	NULL
.	NULL

The	NULL
mobile	NULL
phase	NULL
contained	NULL
a	NULL
mixture	NULL
of	NULL
15	NULL
mM	NULL
KH	NULL
,	NULL
PO	NULL
,	NULL
,	NULL
pH	NULL
4.5	NULL
,	NULL
and	NULL
acetonitrile	NULL
.	NULL

One-ml	NULL
fractions	NULL
were	NULL
collected	NULL
at	NULL
a	NULL
flow	NULL
rate	NULL
of	NULL
1	NULL
ml/min	NULL
over	NULL
a	NULL
linear	NULL
gradient	NULL
of	NULL
decreasing	NULL
acetonitrile	NULL
concentration	NULL
(	NULL
80-50	NULL
%	NULL
)	NULL
,	NULL
and	NULL
aliquots	NULL
were	NULL
sampled	NULL
for	NULL
radioactivity	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

CD48	NULL
oligosaccharides	NULL
were	NULL
obtained	NULL
from	NULL
HL6O	NULL
and	NULL
K562	NULL
cells	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
42	NULL
)	NULL
and	NULL
used	NULL
as	NULL
standards	NULL
.	NULL

Immunoaffinity	NULL
Chromatography	NULL
of	NULL
CD43	NULL
Glycopeptides-Radiola-beled	NULL
CD43	NULL
was	NULL
prepared	NULL
from	NULL
immunoprecipitates	NULL
of	NULL
[	NULL
*Hlglu-cosamine-labeled	NULL
T-lymphoblastoid	NULL
cells	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Glycopeptides	NULL
were	NULL
generated	NULL
by	NULL
digestion	NULL
of	NULL
labeled	NULL
mAb	NULL
J398	NULL
antigen	NULL
with	NULL
5	NULL
mg/ml	NULL
nonspecific	NULL
protease	NULL
(	NULL
Pronase	NULL
)	NULL
in	NULL
0.1	NULL
M	NULL
Tris-HC	NULL
]	NULL
l	NULL
buffer	NULL
containing	NULL
1	NULL
mM	NULL
CaC	NULL
)	NULL
,	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
for	NULL
24	NULL
h	NULL
at	NULL
60	NULL
°C	NULL
under	NULL
a	NULL
toluene	NULL
atmosphere	NULL
.	NULL

The	NULL
digestion	NULL
was	NULL
terminated	NULL
by	NULL
boiling	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Epitope	NULL
integrity	NULL
of	NULL
glycopeptides	NULL
was	NULL
evaluated	NULL
by	NULL
immunoaffinity	NULL
chromatography	NULL
.	NULL

Glycopeptides	NULL
were	NULL
suspended	NULL
in	NULL
50	NULL
ul	NULL
of	NULL
TBS	NULL
buffer	NULL
(	NULL
50	NULL
mm	NULL
Tris-HCl	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
CaCl	NULL
,	NULL
,	NULL
pH	NULL
7.5	NULL
)	NULL
and	NULL
applied	NULL
to	NULL
a	NULL
l-ml	NULL
mAb	NULL
J898-Sepharose	NULL
column	NULL
(	NULL
0.3	NULL
X	NULL
14	NULL
em	NULL
)	NULL
coupled	NULL
with	NULL
6.3	NULL
mg	NULL
of	NULL
antibody	NULL
and	NULL
equilibrated	NULL
in	NULL
TBS	NULL
buffer	NULL
at	NULL
4°C	NULL
.	NULL

Glycopeptides	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
optimally	NULL
interact	NULL
with	NULL
carbohydrate	NULL
binding	NULL
proteins	NULL
coupled	NULL
to	NULL
Sepharose	NULL
at	NULL
this	NULL
protein	NULL
density	NULL
and	NULL
in	NULL
the	NULL
cold	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Fractions	NULL
of	NULL
1	NULL
ml	NULL
were	NULL
collected	NULL
at	NULL
a	NULL
flow	NULL
rate	NULL
of	NULL
1	NULL
ml/h	NULL
with	NULL
all	NULL
steps	NULL
being	NULL
carried	NULL
out	NULL
at	NULL
4°C	NULL
.	NULL

After	NULL
5	NULL
ml	NULL
of	NULL
TBS	NULL
buffer	NULL
had	NULL
been	NULL
applied	NULL
and	NULL
collected	NULL
,	NULL
bound	NULL
material	NULL
was	NULL
eluted	NULL
with	NULL
200	NULL
mM	NULL
glycine	NULL
buffer	NULL
,	NULL
pH	NULL
3.0	NULL
.	NULL

Intact	NULL
,	NULL
undigested	NULL
antigen	NULL
was	NULL
also	NULL
examined	NULL
under	NULL
identical	NULL
chromatographic	NULL
conditions	NULL
.	NULL

Immunoblotting-Anti-CD43	NULL
immunoblotting	NULL
was	NULL
performed	NULL
on	NULL
either	NULL
whole	NULL
cell	NULL
lysates	NULL
or	NULL
on	NULL
immunoprecipitates	NULL
from	NULL
whole	NULL
cell	NULL
lysates	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
lysates	NULL
were	NULL
prepared	NULL
by	NULL
solubilizing	NULL
1-10	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
in	NULL
a	NULL
1-ml	NULL
volume	NULL
of	NULL
Nonidet	NULL
P-40	NULL
lysis	NULL
buffer	NULL
.	NULL

Immune	NULL
complexes	NULL
were	NULL
recovered	NULL
by	NULL
mixing	NULL
GammaBind	NULL
G-Sepharose	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
,	NULL
Inc.	NULL
)	NULL
with	NULL
lysate	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

The	NULL
immunoprecipitates	NULL
were	NULL
solubilized	NULL
in	NULL
Tris-glycine	NULL
SDS	NULL
sample	NULL
buffer	NULL
containing	NULL
2	NULL
mM	NULL
dithiothreitol	NULL
and	NULL
subjected	NULL
to	NULL
6	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
fractionation	NULL
.	NULL

Proteins	NULL
were	NULL
electrotransferred	NULL
onto	NULL
polyvinylidene	NULL
difluoride	NULL
membrane	NULL
,	NULL
and	NULL
antibody	NULL
binding	NULL
was	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
,	NULL
Amersham	NULL
Corp.	NULL
)	NULL
according	NULL
to	NULL
manufacturer	NULL
's	NULL
directions	NULL
.	NULL

Analysis	NULL
of	NULL
Tyrosine	NULL
Phosphorylation-BMS-2	NULL
cells	NULL
were	NULL
adjusted	NULL
to	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
held	NULL
at	NULL
37°C	NULL
.	NULL

Cells	NULL
were	NULL
aliquoted	NULL
in	NULL
1-ml	NULL
volumes	NULL
in	NULL
Eppendorf	NULL
tubes	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
27688	NULL
containing	NULL
all	NULL
test	NULL
reagents	NULL
and	NULL
placed	NULL
in	NULL
a	NULL
37°C	NULL
heat	NULL
block	NULL
for	NULL
the	NULL
desired	NULL
length	NULL
of	NULL
time	NULL
.	NULL

Reactions	NULL
were	NULL
terminated	NULL
by	NULL
spinning	NULL
the	NULL
tubes	NULL
for	NULL
30	NULL
s	NULL
at	NULL
4°C	NULL
,	NULL
decanting	NULL
,	NULL
and	NULL
solubilizing	NULL
the	NULL
cell	NULL
pellets	NULL
in	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
containing	NULL
protease	NULL
,	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
and	NULL
immunoprecipitates	NULL
were	NULL
analyzed	NULL
for	NULL
phosphotyrosine	NULL
content	NULL
by	NULL
immunoblotting	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Gel	NULL
Mobility	NULL
Shift	NULL
Assay-Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
approximately	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
using	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
procedure	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
45	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
for	NULL
5	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
in	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
NaCl	NULL
,	NULL
0.25	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
followed	NULL
by	NULL
centrifugation	NULL
and	NULL
salt	NULL
extraction	NULL
of	NULL
nuclei	NULL
in	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
0.42	NULL
M	NULL
NaCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.25	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
nuclear	NULL
extract	NULL
was	NULL
centrifuged	NULL
at	NULL
14,000	NULL
rpm	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
the	NULL
supernatants	NULL
were	NULL
used	NULL
for	NULL
the	NULL
electrophoretic	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

The	NULL
electrophoretic	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
was	NULL
essentially	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
procedure	NULL
of	NULL
Sen	NULL
and	NULL
Baltimore	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Double-stranded	NULL
oligonucleotide	NULL
probes	NULL
for	NULL
the	NULL
recognition	NULL
sequence	NULL
of	NULL
NF-xB	NULL
(	NULL
5'-GATCCGAGGGGACTTTC-CGCTGGGGACTTTCCAGG-3	NULL
'	NULL
)	NULL
,	NULL
octamer	NULL
(	NULL
5'-TGTCGAATGCAAAT-CACTAGAA-3	NULL
'	NULL
)	NULL
,	NULL
and	NULL
AP-1	NULL
(	NULL
5-CGCTTGATGAGTCAGCCATG	NULL
AA-3	NULL
'	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
,	NULL
and	NULL
IRE	NULL
(	NULL
5'-AAGTACTTT	NULL
CAG	NULL
TTTCATATTACTCTA-3	NULL
'	NULL
)	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
,	NULL
and	NULL
radiolabeled	NULL
at	NULL
the	NULL
5'-end	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
man-ufacturer	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
nuclear	NULL
extract	NULL
protein	NULL
(	NULL
8	NULL
pg	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
*°P-labeled	NULL
oligonucleotide	NULL
probes	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
native	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
radioactivity	NULL
quantitated	NULL
by	NULL
autoradiography	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Confocal	NULL
Microscopy-BMS-2	NULL
cells	NULL
and	NULL
PHA-activated	NULL
peripheral	NULL
blood	NULL
T-cells	NULL
were	NULL
analyzed	NULL
for	NULL
expression	NULL
and	NULL
cellular	NULL
localization	NULL
of	NULL
the	NULL
J398	NULL
antigen	NULL
.	NULL

BMS-2	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
PE-streptavidin/bio-tinylated	NULL
mAb	NULL
J398	NULL
and	NULL
FITC-conjugated	NULL
mAb	NULL
G10-2	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
,	NULL
fixed	NULL
on	NULL
ice	NULL
in	NULL
4	NULL
%	NULL
paraformaldehyde/PBS	NULL
for	NULL
20	NULL
min	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
PBS	NULL
with	NULL
0.02	NULL
%	NULL
NaN	NULL
,	NULL
.	NULL

Peripheral	NULL
blood	NULL
T-cells	NULL
were	NULL
isolated	NULL
from	NULL
normal	NULL
volunteers	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
and	NULL
sheep	NULL
red	NULL
blood	NULL
cell	NULL
rosetting	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Activated	NULL
T-cells	NULL
(	NULL
>	NULL
95	NULL
%	NULL
CD38*	NULL
)	NULL
cultured	NULL
in	NULL
PHA	NULL
for	NULL
72	NULL
h	NULL
were	NULL
fixed	NULL
on	NULL
ice	NULL
in	NULL
4	NULL
%	NULL
paraformaldehyde/PBS	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
PBS	NULL
and	NULL
permeabilized	NULL
in	NULL
0.1	NULL
%	NULL
saponin/PBS	NULL
.	NULL

Samples	NULL
were	NULL
washed	NULL
and	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
either	NULL
mAb	NULL
J898	NULL
or	NULL
FLOPC-21	NULL
(	NULL
IgGS	NULL
isotype-matched	NULL
control	NULL
)	NULL
at	NULL
10	NULL
ug/ml	NULL
followed	NULL
by	NULL
a	NULL
similar	NULL
incubation	NULL
with	NULL
FITC-conjugated	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
culture	NULL
medium	NULL
prior	NULL
to	NULL
analysis	NULL
using	NULL
the	NULL
Bio-Rad	NULL
MRC	NULL
1024	NULL
confocal	NULL
microscope	NULL
.	NULL

RESULTS	NULL
mAb	NULL
J393-induced	NULL
Apoptosis	NULL
in	NULL
Cultured	NULL
T-lymphoblastoid	NULL
Cells-Mice	NULL
immunized	NULL
with	NULL
the	NULL
human	NULL
T-lymphoblastoid	NULL
cell	NULL
line	NULL
,	NULL
Jurkat	NULL
,	NULL
produced	NULL
an	NULL
antibody	NULL
termed	NULL
J393	NULL
that	NULL
induced	NULL
homotypic	NULL
adhesion	NULL
and	NULL
then	NULL
death	NULL
of	NULL
these	NULL
cells	NULL
in	NULL
culture	NULL
.	NULL

Within	NULL
the	NULL
first	NULL
hour	NULL
of	NULL
treatment	NULL
Jurkat	NULL
cells	NULL
underwent	NULL
pronounced	NULL
homotypic	NULL
adhesion	NULL
,	NULL
forming	NULL
large	NULL
cellular	NULL
aggre-gates	NULL
.	NULL

Over	NULL
a	NULL
period	NULL
of	NULL
4-6	NULL
h	NULL
a	NULL
certain	NULL
proportion	NULL
of	NULL
the	NULL
cell	NULL
population	NULL
began	NULL
to	NULL
die	NULL
.	NULL

Under	NULL
the	NULL
phase	NULL
contrast	NULL
microscope	NULL
,	NULL
morphologic	NULL
changes	NULL
were	NULL
observed	NULL
that	NULL
were	NULL
characteristic	NULL
of	NULL
the	NULL
type	NULL
of	NULL
programmed	NULL
cell	NULL
death	NULL
referred	NULL
to	NULL
as	NULL
apoptosis	NULL
(	NULL
membrane	NULL
blebbing	NULL
,	NULL
cellular	NULL
shrinkage	NULL
,	NULL
and	NULL
nuclear	NULL
conden-sation	NULL
)	NULL
.	NULL

As	NULL
an	NULL
indicator	NULL
of	NULL
death	NULL
,	NULL
cells	NULL
were	NULL
monitored	NULL
for	NULL
the	NULL
uptake	NULL
of	NULL
the	NULL
fluorescent	NULL
compound	NULL
propidium	NULL
iodide	NULL
(	NULL
PT	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
a	NULL
function	NULL
of	NULL
size	NULL
versus	NULL
fluorescence	NULL
intensity	NULL
to	NULL
determine	NULL
the	NULL
level	NULL
of	NULL
killing	NULL
and	NULL
the	NULL
degree	NULL
of	NULL
nuclear	NULL
damage	NULL
.	NULL

By	NULL
comparison	NULL
of	NULL
Fig	NULL
.	NULL

1A	NULL
with	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
the	NULL
percent	NULL
of	NULL
dead	NULL
or	NULL
dying	NULL
cells	NULL
detected	NULL
by	NULL
PI	NULL
permeability	NULL
(	NULL
quadrants	NULL
2	NULL
and	NULL
3	NULL
)	NULL
or	NULL
decrease	NULL
in	NULL
forward	NULL
light	NULL
scatter	NULL
(	NULL
quadrants	NULL
1	NULL
and	NULL
2	NULL
)	NULL
increased	NULL
from	NULL
1.9	NULL
to	NULL
52.9	NULL
%	NULL
as	NULL
a	NULL
result	NULL
of	NULL
mAb	NULL
J393	NULL
treatment	NULL
(	NULL
sum	NULL
of	NULL
quadrants	NULL
1	NULL
,	NULL
2	NULL
,	NULL
and	NULL
3	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
number	NULL
of	NULL
Pl-impermeable	NULL
cells	NULL
or	NULL
viable	NULL
cells	NULL
decreased	NULL
accordingly	NULL
(	NULL
quadrant	NULL
4	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
quadrants	NULL
1	NULL
and	NULL
2	NULL
represent	NULL
a	NULL
population	NULL
of	NULL
cells	NULL
with	NULL
decreased	NULL
forward	NULL
light	NULL
scattering	NULL
properties	NULL
,	NULL
reflecting	NULL
a	NULL
decrease	NULL
in	NULL
cell	NULL
size	NULL
(	NULL
shrinkage	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
killing	NULL
of	NULL
Jurkat	NULL
cells	NULL
by	NULL
mAb	NULL
J393	NULL
was	NULL
both	NULL
concentration-	NULL
and	NULL
time-depend-ent	NULL
,	NULL
reaching	NULL
a	NULL
maximum	NULL
of	NULL
25-50	NULL
%	NULL
dead	NULL
after	NULL
a	NULL
24-h	NULL
treatment	NULL
with	NULL
5	NULL
ug/ml	NULL
of	NULL
antibody	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
Apoptosis	NULL
in	NULL
T-cells	NULL
by	NULL
Anti-CD43	NULL
mAb	NULL
Fluorescence	NULL
Intensity	NULL
i	NULL
1	NULL
1	NULL
§	NULL
4	NULL
a	NULL
@	NULL
i	NULL
n	NULL
a	NULL
®	NULL
a	NULL
a	NULL
a	NULL
Forward	NULL
Light	NULL
Scatter	NULL
G	NULL
,	NULL
/	NULL
G	NULL
,	NULL
chromatin	NULL
--	NULL
»	NULL
Nuclei	NULL
Number	NULL
DNA	NULL
Fluorescence	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Apoptosis	NULL
in	NULL
T-lymphoblastoid	NULL
cells	NULL
is	NULL
induced	NULL
by	NULL
mAb	NULL
J898	NULL
.	NULL

Actively	NULL
growing	NULL
Jurkat	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°/ml	NULL
)	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
(	NULL
A	NULL
)	NULL
without	NULL
or	NULL
(	NULL
B	NULL
)	NULL
with	NULL
5	NULL
ug/ml	NULL
mAb	NULL
J8938	NULL
followed	NULL
by	NULL
cytofluorimetric	NULL
analysis	NULL
of	NULL
propidium	NULL
iodide	NULL
(	NULL
Pl	NULL
)	NULL
uptake	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

The	NULL
percent	NULL
of	NULL
total	NULL
population	NULL
falling	NULL
within	NULL
each	NULL
quadrant	NULL
is	NULL
given	NULL
.	NULL

A	NULL
decrease	NULL
in	NULL
cells	NULL
within	NULL
quadrant	NULL
4	NULL
indicates	NULL
an	NULL
increase	NULL
in	NULL
cell	NULL
death	NULL
.	NULL

C	NULL
,	NULL
cells	NULL
treated	NULL
with	NULL
(	NULL
Ratched	NULL
)	NULL
or	NULL
without	NULL
(	NULL
solid	NULL
)	NULL
5	NULL
ug/ml	NULL
mAb	NULL
J898	NULL
for	NULL
24	NULL
h	NULL
were	NULL
exposed	NULL
to	NULL
Triton	NULL
X-100	NULL
lysis	NULL
buffer	NULL
containing	NULL
PI	NULL
,	NULL
and	NULL
the	NULL
nuclei	NULL
were	NULL
cytofluorimetrically	NULL
analyzed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Fluorescence	NULL
intensity	NULL
below	NULL
that	NULL
of	NULL
intact	NULL
G/G	NULL
,	NULL
chromatin	NULL
indicates	NULL
the	NULL
presence	NULL
of	NULL
hypodiploid	NULL
cells	NULL
in	NULL
the	NULL
original	NULL
cell	NULL
population	NULL
.	NULL

Apoptosis	NULL
may	NULL
be	NULL
associated	NULL
with	NULL
the	NULL
breakdown	NULL
of	NULL
DNA	NULL
as	NULL
a	NULL
result	NULL
of	NULL
increased	NULL
endonuclease	NULL
activity	NULL
.	NULL

To	NULL
further	NULL
assess	NULL
whether	NULL
cell	NULL
death	NULL
induced	NULL
by	NULL
mAb	NULL
J393	NULL
was	NULL
characteristic	NULL
of	NULL
apoptosis	NULL
,	NULL
PI	NULL
was	NULL
allowed	NULL
to	NULL
intercalate	NULL
with	NULL
the	NULL
DNA	NULL
in	NULL
Jurkat	NULL
cell	NULL
lysates	NULL
and	NULL
the	NULL
nuclear	NULL
staining	NULL
analyzed	NULL
cytofluorimetrically	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
mAb	NULL
J393	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
population	NULL
of	NULL
hypodiploid	NULL
cells	NULL
as	NULL
measured	NULL
by	NULL
a	NULL
3-fold	NULL
increase	NULL
in	NULL
fluorescence	NULL
intensity	NULL
below	NULL
that	NULL
of	NULL
intact	NULL
G	NULL
,	NULL
/G	NULL
,	NULL
chromatin	NULL
(	NULL
26	NULL
%	NULL
of	NULL
the	NULL
total	NULL
DNA	NULL
in	NULL
treated	NULL
cultures	NULL
versus	NULL
8	NULL
%	NULL
in	NULL
the	NULL
untreated	NULL
population	NULL
)	NULL
.	NULL

Since	NULL
apoptosis	NULL
has	NULL
been	NULL
regarded	NULL
as	NULL
fundamentally	NULL
important	NULL
to	NULL
homeostasis	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
,	NULL
it	NULL
was	NULL
of	NULL
interest	NULL
to	NULL
identify	NULL
the	NULL
antigen	NULL
for	NULL
mAb	NULL
J8398	NULL
.	NULL

NH	NULL
-terminal	NULL
Protein	NULL
Sequence	NULL
of	NULL
the	NULL
mAb	NULL
J393	NULL
Antigen-The	NULL
antigen	NULL
for	NULL
mAb	NULL
J393	NULL
was	NULL
isolated	NULL
from	NULL
detergent	NULL
lysates	NULL
of	NULL
Jurkat	NULL
cells	NULL
by	NULL
affinity	NULL
chromatography	NULL
and	NULL
purified	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

The	NULL
140-kDa	NULL
protein	NULL
was	NULL
then	NULL
examined	NULL
for	NULL
its	NULL
primary	NULL
structure	NULL
.	NULL

nal	NULL
amino	NULL
acid	NULL
sequence	NULL
analysis	NULL
of	NULL
the	NULL
mAb	NULL
J393	NULL
antigen	NULL
resulted	NULL
in	NULL
13	NULL
of	NULL
the	NULL
first	NULL
15	NULL
NH	NULL
,	NULL
-terminal	NULL
amino	NULL
acid	NULL
positions	NULL
to	NULL
be	NULL
assigned	NULL
(	NULL
STTAVQTPT	NULL
(	NULL
X	NULL
)	NULL
GE	NULL
(	NULL
X	NULL
)	NULL
LV	NULL
)	NULL
.	NULL

This	NULL
sequence	NULL
was	NULL
searched	NULL
in	NULL
the	NULL
Swiss-Prot	NULL
data	NULL
base	NULL
for	NULL
homology	NULL
to	NULL
known	NULL
proteins	NULL
.	NULL

Excluding	NULL
the	NULL
two	NULL
unassigned	NULL
positions	NULL
,	NULL
the	NULL
protein	NULL
sequence	NULL
obtained	NULL
for	NULL
the	NULL
mAb	NULL
J393	NULL
antigen	NULL
was	NULL
100	NULL
%	NULL
homol-ogous	NULL
to	NULL
the	NULL
NH	NULL
,	NULL
-terminal	NULL
region	NULL
of	NULL
human	NULL
CD43/leukosialin	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Since	NULL
no	NULL
intron	NULL
structures	NULL
exist	NULL
in	NULL
the	NULL
coding	NULL
region	NULL
of	NULL
the	NULL
human	NULL
CD43	NULL
gene	NULL
allowing	NULL
for	NULL
alternative	NULL
splicing	NULL
of	NULL
exons	NULL
(	NULL
21	NULL
)	NULL
,	NULL
we	NULL
take	NULL
this	NULL
partial	NULL
sequence	NULL
information	NULL
to	NULL
be	NULL
adequate	NULL
in	NULL
identifying	NULL
the	NULL
mAb	NULL
J893	NULL
antigen	NULL
as	NULL
CD43	NULL
.	NULL

Isoform	NULL
Specificity	NULL
of	NULL
mAb	NULL
J393-Since	NULL
several	NULL
antibodies	NULL
to	NULL
CD43	NULL
have	NULL
been	NULL
previously	NULL
described	NULL
,	NULL
we	NULL
questioned	NULL
whether	NULL
they	NULL
were	NULL
functionally	NULL
similar	NULL
to	NULL
mAb	NULL
J8983	NULL
.	NULL

Cultures	NULL
of	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
soluble	NULL
forms	NULL
of	NULL
the	NULL
anti-CD43	NULL
mAbs	NULL
G10-2	NULL
,	NULL
G19-1	NULL
,	NULL
and	NULL
J393	NULL
and	NULL
monitored	NULL
for	NULL
apoptosis	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

While	NULL
all	NULL
three	NULL
anti	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Induction	NULL
of	NULL
Apoptosis	NULL
in	NULL
T-cells	NULL
by	NULL
Anti-CD43	NULL
mAb	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

T-lymphoblastoid	NULL
cells	NULL
co-express	NULL
antigenically	NULL
distinct	NULL
isoforms	NULL
of	NULL
CD43	NULL
.	NULL

Actively	NULL
growing	NULL
Jurkat	NULL
cells	NULL
were	NULL
immunostained	NULL
with	NULL
phycoerythrin-labeled	NULL
mAb	NULL
J898	NULL
(	NULL
red	NULL
)	NULL
and	NULL
FITC-conjugated	NULL
mAb	NULL
G19-1	NULL
(	NULL
green	NULL
)	NULL
and	NULL
analyzed	NULL
for	NULL
two-color	NULL
fluorescence	NULL
(	NULL
red	NULL
/	NULL
green	NULL
)	NULL
by	NULL
confocal	NULL
microscopy	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Both	NULL
red	NULL
and	NULL
green	NULL
fluorescence	NULL
appear	NULL
to	NULL
be	NULL
differentially	NULL
distributed	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
.	NULL

Yellow	NULL
fluorescence	NULL
depicts	NULL
regions	NULL
of	NULL
colocalization	NULL
.	NULL

CD43	NULL
antibodies	NULL
induced	NULL
observable	NULL
homotypic	NULL
adhesion	NULL
,	NULL
only	NULL
mAb	NULL
J393	NULL
induced	NULL
apoptosis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
cells	NULL
not	NULL
killed	NULL
by	NULL
mAb	NULL
J398	NULL
were	NULL
growth-arrested	NULL
,	NULL
whereas	NULL
cells	NULL
treated	NULL
with	NULL
mAb	NULL
G10-2	NULL
or	NULL
mAbG19-1	NULL
continued	NULL
to	NULL
divide	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
double-stained	NULL
with	NULL
the	NULL
fluorescent	NULL
conjugates	NULL
PE-J393	NULL
and	NULL
FITC-G19-1	NULL
and	NULL
examined	NULL
using	NULL
confocal	NULL
microscopy	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
the	NULL
two-color	NULL
staining	NULL
pattern	NULL
that	NULL
was	NULL
observed	NULL
revealed	NULL
that	NULL
the	NULL
epitopes	NULL
reactive	NULL
with	NULL
these	NULL
two	NULL
antibodies	NULL
resided	NULL
on	NULL
distinct	NULL
molecules	NULL
that	NULL
segregated	NULL
independently	NULL
in	NULL
the	NULL
plane	NULL
of	NULL
the	NULL
membrane	NULL
.	NULL

This	NULL
indicated	NULL
that	NULL
single	NULL
cells	NULL
in	NULL
the	NULL
population	NULL
were	NULL
co-expressing	NULL
two	NULL
distinct	NULL
alternatively	NULL
glycosylated	NULL
isoforms	NULL
of	NULL
CD43	NULL
;	NULL
however	NULL
,	NULL
only	NULL
the	NULL
J393/CD43	NULL
isoform	NULL
was	NULL
involved	NULL
in	NULL
signaling	NULL
an	NULL
apoptotic	NULL
response	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
looked	NULL
for	NULL
structural	NULL
differences	NULL
between	NULL
.	NULL

these	NULL
isoforms	NULL
.	NULL

Carbohydrate	NULL
Analysis	NULL
of	NULL
the	NULL
J393/CD43	NULL
Isoform-Diver-sity	NULL
among	NULL
human	NULL
CD43	NULL
molecules	NULL
has	NULL
been	NULL
ascribed	NULL
to	NULL
post-translational	NULL
modifications	NULL
of	NULL
a	NULL
single	NULL
gene	NULL
product	NULL
(	NULL
20-22	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
carbohydrate	NULL
structure	NULL
of	NULL
the	NULL
mAb	NULL
J393	NULL
antigen	NULL
in	NULL
comparison	NULL
with	NULL
that	NULL
of	NULL
other	NULL
mAb-specific	NULL
isoforms	NULL
of	NULL
CD43	NULL
.	NULL

Analysis	NULL
was	NULL
limited	NULL
to	NULL
O-linked	NULL
sugars	NULL
since	NULL
CD43	NULL
is	NULL
known	NULL
to	NULL
contain	NULL
only	NULL
one	NULL
potential	NULL
N-linked	NULL
glycosylation	NULL
site	NULL
and	NULL
80	NULL
potential	NULL
O-linked	NULL
sites	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Different	NULL
isoforms	NULL
of	NULL
CD43	NULL
were	NULL
immunoprecipitated	NULL
from	NULL
cellular	NULL
lysates	NULL
of	NULL
T-lymphoblastoid	NULL
cells	NULL
using	NULL
mAb	NULL
J393	NULL
,	NULL
mAb	NULL
T-305	NULL
,	NULL
and	NULL
mAb	NULL
G10-2	NULL
,	NULL
and	NULL
the	NULL
attached	NULL
radiolabeled	NULL
carbohydrate	NULL
27689	NULL
TABLE	NULL
I	NULL
Structures	NULL
and	NULL
relative	NULL
amounts	NULL
of	NULL
the	NULL
O-linked	NULL
oligosaccharides	NULL
found	NULL
on	NULL
CD43	NULL
CD43	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
[	NULL
°H	NULL
]	NULL
glucosamine-labeled	NULL
T-cells	NULL
.	NULL

The	NULL
radioactive	NULL
O-linked	NULL
chains	NULL
obtained	NULL
after	NULL
alkaline	NULL
borohydride	NULL
treatment	NULL
of	NULL
CD43	NULL
were	NULL
separated	NULL
by	NULL
high	NULL
performance	NULL
liquid	NULL
chromatography	NULL
.	NULL

Data	NULL
are	NULL
listed	NULL
as	NULL
percent	NULL
of	NULL
total	NULL
``	NULL
H-oligosaccharides	NULL
recovered	NULL
.	NULL

CD43	NULL
oligosaccharides	NULL
Egg	NULL
,	NULL
(	NULL
£53155	NULL
T1332	NULL
}	NULL
;	NULL
%	NULL
GalNAcOH	NULL
82	NULL
15	NULL
19	NULL
12	NULL
5	NULL
0	NULL
NeuNAca2-3Gal1-3GalINAcOH	NULL
6	NULL
0	NULL
10	NULL
NeuNAca2	NULL
\6	NULL
NeuNAca2-3Gal1-3GalINAcOH	NULL
0	NULL
30	NULL
11	NULL
NeuNAca2-3Gal1-4GleNAcf1	NULL
A	NULL
6	NULL
0	NULL
50	NULL
60	NULL
*	NULL
Immunoprecipitated	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
mAb	NULL
G10-2	NULL
and	NULL
mAb	NULL
T-805	NULL
did	NULL
not	NULL
immunoprecipitate	NULL
in	NULL
NP-40	NULL
lysis	NULL
buffer	NULL
)	NULL
.	NULL

*	NULL
Immunoprecipitated	NULL
from	NULL
HPB-ALL	NULL
cells	NULL
(	NULL
mAb	NULL
J898	NULL
did	NULL
not	NULL
immunoprecipitate	NULL
in	NULL
NP-40	NULL
lysis	NULL
buffer	NULL
)	NULL
.	NULL

was	NULL
analyzed	NULL
according	NULL
to	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
,	NULL
82	NULL
%	NULL
of	NULL
the	NULL
total	NULL
serine/threonine-linked	NULL
carbohydrate	NULL
of	NULL
the	NULL
J393/CD43	NULL
isoform	NULL
in	NULL
Jurkat	NULL
cells	NULL
were	NULL
of	NULL
the	NULL
GaINAc	NULL
monosaccharide	NULL
class	NULL
and	NULL
12	NULL
%	NULL
were	NULL
of	NULL
the	NULL
GalB1-3GaINAc	NULL
disaccharide	NULL
class	NULL
.	NULL

The	NULL
remaining	NULL
6	NULL
%	NULL
of	NULL
the	NULL
O-linked	NULL
sugars	NULL
of	NULL
the	NULL
J393/CD43	NULL
molecule	NULL
contained	NULL
sialic	NULL
acid	NULL
and	NULL
were	NULL
of	NULL
the	NULL
NeuNAco2-3GalB1-3GaINAc	NULL
trisaccharide	NULL
class	NULL
.	NULL

By	NULL
comparison	NULL
,	NULL
80	NULL
%	NULL
of	NULL
the	NULL
O-linked	NULL
sugars	NULL
attached	NULL
to	NULL
the	NULL
G10-2/CD43	NULL
isoform	NULL
in	NULL
HPB-ALL	NULL
cells	NULL
were	NULL
made	NULL
up	NULL
of	NULL
sialylated	NULL
tri-	NULL
,	NULL
tetra-	NULL
,	NULL
and	NULL
hexasaccharides	NULL
with	NULL
the	NULL
remaining	NULL
20	NULL
%	NULL
being	NULL
predominantly	NULL
monosaccharides	NULL
.	NULL

The	NULL
T-305/CD43	NULL
isoform	NULL
in	NULL
HPB-ALL	NULL
cells	NULL
displayed	NULL
an	NULL
oligosaccharide	NULL
structure	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
G10-2/CD43	NULL
isoform	NULL
;	NULL
however	NULL
,	NULL
it	NULL
contained	NULL
less	NULL
tetrasaccharide	NULL
and	NULL
more	NULL
hexasaccharide	NULL
moieties	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Neuraminidase-resistant	NULL
Property	NULL
of	NULL
the	NULL
mAb	NULL
J393	NULL
Epitope-Antibodies	NULL
for	NULL
CD43	NULL
have	NULL
been	NULL
characterized	NULL
as	NULL
to	NULL
their	NULL
epitope	NULL
requirement	NULL
for	NULL
terminal	NULL
sialic	NULL
acid	NULL
sugar	NULL
residues	NULL
.	NULL

The	NULL
anti-CD43	NULL
mAb	NULL
T-305	NULL
has	NULL
been	NULL
described	NULL
as	NULL
being	NULL
sialic	NULL
acid-independent	NULL
,	NULL
since	NULL
the	NULL
epitope	NULL
is	NULL
resistant	NULL
to	NULL
digestion	NULL
by	NULL
neuraminidase	NULL
(	NULL
9	NULL
)	NULL
,	NULL
while	NULL
the	NULL
immunoreactivities	NULL
of	NULL
several	NULL
other	NULL
anti-CD43	NULL
antibodies	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
sensitive	NULL
to	NULL
neuraminidase	NULL
treatment	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

The	NULL
histograms	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
were	NULL
generated	NULL
by	NULL
immunostaining	NULL
Jurkat	NULL
and	NULL
HPB-ALL	NULL
cells	NULL
with	NULL
mAb	NULL
G10-2	NULL
or	NULL
mAb	NULL
J393	NULL
before	NULL
and	NULL
after	NULL
V.	NULL
cholerae	NULL
neuraminidase	NULL
treatment	NULL
.	NULL

The	NULL
mAb	NULL
G10-2	NULL
demonstrated	NULL
an	NULL
absolute	NULL
requirement	NULL
for	NULL
sialic	NULL
acid	NULL
residues	NULL
in	NULL
maintaining	NULL
immunoreactivity	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

Mean	NULL
channel	NULL
fluorescence	NULL
decreased	NULL
from	NULL
a	NULL
value	NULL
of	NULL
245	NULL
to	NULL
a	NULL
value	NULL
of	NULL
11	NULL
as	NULL
a	NULL
result	NULL
of	NULL
neuraminidase	NULL
treatment	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
sialic	NULL
acid	NULL
was	NULL
not	NULL
required	NULL
for	NULL
antigen	NULL
recognition	NULL
by	NULL
mAb	NULL
J393	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
immunoreactivity	NULL
of	NULL
mAb	NULL
J393	NULL
increased	NULL
following	NULL
neuraminidase	NULL
treatment	NULL
,	NULL
which	NULL
was	NULL
most	NULL
notable	NULL
in	NULL
HPB-ALL	NULL
cells	NULL
.	NULL

Enzymatic	NULL
digestion	NULL
by	NULL
neuraminidases	NULL
from	NULL
either	NULL
C.	NULL
perfringens	NULL
or	NULL
A.	NULL
ure-afaciens	NULL
sources	NULL
gave	NULL
similar	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Protease-sensitive	NULL
Property	NULL
of	NULL
the	NULL
mAb	NULL
J393	NULL
Epitope-Jurkat	NULL
cells	NULL
are	NULL
known	NULL
to	NULL
possess	NULL
a	NULL
deficiency	NULL
in	NULL
B1,3-galactosyltransferase	NULL
activity	NULL
(	NULL
49	NULL
)	NULL
resulting	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
an	NULL
alternatively	NULL
glycosylated	NULL
isoform	NULL
of	NULL
CD43	NULL
bearing	NULL
the	NULL
GaINAc-Ser/	NULL
Thr	NULL
cluster	NULL
structure	NULL
of	NULL
Tn	NULL
antigen	NULL
(	NULL
50	NULL
)	NULL
.	NULL

The	NULL
carbohydrate	NULL
analysis	NULL
of	NULL
the	NULL
mAb	NULL
J393	NULL
antigen	NULL
indicated	NULL
structural	NULL
similarity	NULL
with	NULL
this	NULL
Tn	NULL
antigen-containing	NULL
isoform	NULL
of	NULL
CD43	NULL
;	NULL
however	NULL
,	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
27690	NULL
Cell	NULL
Number	NULL
10	NULL
o	NULL
1000	NULL
Fluorescence	NULL
Intensity	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

The	NULL
CD43-specific	NULL
epitope	NULL
for	NULL
mAb	NULL
J3938	NULL
is	NULL
resistant	NULL
to	NULL
digestion	NULL
by	NULL
sialidase	NULL
.	NULL

Cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
from	NULL
the	NULL
T-cell	NULL
lines	NULL
,	NULL
Jurkat	NULL
and	NULL
HPB-ALL	NULL
,	NULL
were	NULL
immunostained	NULL
with	NULL
anti-CD43	NULL
antibodies	NULL
following	NULL
treatment	NULL
for	NULL
60	NULL
min	NULL
at	NULL
37°C	NULL
in	NULL
culture	NULL
medium	NULL
with	NULL
(	NULL
--	NULL
-	NULL
)	NULL
and	NULL
without	NULL
(	NULL
-	NULL
)	NULL
0.05	NULL
units/ml	NULL
Vibrio	NULL
cholerae	NULL
neuraminidase	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Changes	NULL
in	NULL
fluorescence	NULL
intensity	NULL
as	NULL
compared	NULL
with	NULL
isotype-matched	NULL
control	NULL
antibodies	NULL
(	NULL
***	NULL
)	NULL
were	NULL
detected	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

A	NULL
,	NULL
HPB-ALL	NULL
cells	NULL
immunostained	NULL
with	NULL
mAb	NULL
G10-2	NULL
.	NULL

B	NULL
,	NULL
HPB-ALL	NULL
cells	NULL
immunostained	NULL
with	NULL
mAb	NULL
J898	NULL
.	NULL

C	NULL
,	NULL
Jurkat	NULL
cells	NULL
immunostained	NULL
with	NULL
mAb	NULL
J898	NULL
.	NULL

we	NULL
were	NULL
unable	NULL
to	NULL
demonstrate	NULL
immunostaining	NULL
by	NULL
mAb	NULL
J893	NULL
of	NULL
Tn	NULL
antigen-positive	NULL
CEM	NULL
cells	NULL
and	NULL
certain	NULL
Tn-expressing	NULL
human	NULL
carcinoma	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
presented	NULL
)	NULL
.	NULL

This	NULL
result	NULL
suggested	NULL
that	NULL
the	NULL
epitope	NULL
for	NULL
mAb	NULL
J393	NULL
differed	NULL
from	NULL
that	NULL
described	NULL
for	NULL
other	NULL
T	NULL
'	NULL
n	NULL
antibodies	NULL
.	NULL

In	NULL
order	NULL
to	NULL
characterize	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
epitopic	NULL
structure	NULL
recognized	NULL
by	NULL
mAb	NULL
J393	NULL
,	NULL
[	NULL
'	NULL
H	NULL
]	NULL
glucosamine-labeled	NULL
J393	NULL
antigen	NULL
was	NULL
proteolytically	NULL
digested	NULL
into	NULL
glycopeptides	NULL
and	NULL
tested	NULL
for	NULL
reactivity	NULL
on	NULL
a	NULL
mAb	NULL
J393-Sepharose	NULL
affinity	NULL
column	NULL
under	NULL
conditions	NULL
that	NULL
promote	NULL
the	NULL
retention	NULL
of	NULL
glycopeptides	NULL
(	NULL
see	NULL
``	NULL
Experimental	NULL
Procedures	NULL
``	NULL
)	NULL
.	NULL

Many	NULL
anti-carbohydrate	NULL
antibodies	NULL
bind	NULL
to	NULL
carbohydrate	NULL
antigens	NULL
under	NULL
these	NULL
experimental	NULL
conditions	NULL
(	NULL
51	NULL
,	NULL
52	NULL
)	NULL
.	NULL

As	NULL
demonstrated	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
87	NULL
%	NULL
of	NULL
the	NULL
radioactivity	NULL
associated	NULL
with	NULL
intact	NULL
CD43	NULL
required	NULL
elution	NULL
at	NULL
acidic	NULL
pH	NULL
,	NULL
indicating	NULL
a	NULL
strong	NULL
anti-gen-antibody	NULL
interaction	NULL
with	NULL
the	NULL
column	NULL
substrate	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
93	NULL
%	NULL
of	NULL
the	NULL
radioactivity	NULL
associated	NULL
with	NULL
CD43	NULL
glycopeptides	NULL
eluted	NULL
at	NULL
neutral	NULL
pH	NULL
,	NULL
indicating	NULL
very	NULL
weak	NULL
interaction	NULL
with	NULL
the	NULL
column	NULL
substrate	NULL
and	NULL
loss	NULL
of	NULL
antigenic	NULL
valency	NULL
.	NULL

A	NULL
minor	NULL
proportion	NULL
(	NULL
7	NULL
%	NULL
)	NULL
of	NULL
CD43	NULL
digest	NULL
that	NULL
eluted	NULL
under	NULL
acid	NULL
conditions	NULL
may	NULL
represent	NULL
larger	NULL
glycoprotein	NULL
fragments	NULL
resulting	NULL
from	NULL
incomplete	NULL
proteolysis	NULL
.	NULL

Intact	NULL
[	NULL
°H	NULL
]	NULL
glucosamine-labeled	NULL
mAb	NULL
G10-2	NULL
antigen	NULL
isolated	NULL
from	NULL
the	NULL
HPB-ALL	NULL
cell	NULL
line	NULL
failed	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
mAb	NULL
J393	NULL
affinity	NULL
substrate	NULL
,	NULL
demonstrating	NULL
the	NULL
specificity	NULL
for	NULL
antigen	NULL
(	NULL
data	NULL
not	NULL
presented	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
specific	NULL
protein	NULL
and	NULL
carbohydrate	NULL
domains	NULL
of	NULL
CD43	NULL
are	NULL
important	NULL
for	NULL
high-avidity	NULL
recognition	NULL
of	NULL
epitope	NULL
by	NULL
mAb	NULL
J8983	NULL
.	NULL

Cell-surface	NULL
Interactions	NULL
That	NULL
Enhance	NULL
J393/CD43-Mediated	NULL
Apoptosis-It	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
that	NULL
certain	NULL
isoforms	NULL
of	NULL
CD43	NULL
can	NULL
function	NULL
as	NULL
accessory	NULL
molecules	NULL
in	NULL
CD3/TcR-stimulated	NULL
T-cell	NULL
activation	NULL
(	NULL
11	NULL
,	NULL
28-31	NULL
)	NULL
and	NULL
may	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
cell-cell	NULL
interactions	NULL
by	NULL
binding	NULL
to	NULL
the	NULL
integrin	NULL
family	NULL
adhesion	NULL
molecule	NULL
ICAM-1	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
ligating	NULL
additional	NULL
surface	NULL
molecules	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
mAb	NULL
J393	NULL
to	NULL
induce	NULL
apoptosis	NULL
.	NULL

As	NULL
represented	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
concomitant	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
mAb	NULL
J393	NULL
plus	NULL
Induction	NULL
of	NULL
Apoptosis	NULL
in	NULL
T-cells	NULL
by	NULL
Anti-CD43	NULL
mAb	NULL
2000	NULL
o	NULL
pH	NULL
3.0	NULL
4C	NULL
1500	NULL
-	NULL
{	NULL
If	NULL
i	NULL
|	NULL
1000	NULL
Counts/Minute	NULL
°H	NULL
500	NULL
0	NULL
2	NULL
4	NULL
60	NULL
8	NULL
10	NULL
12	NULL
Elution	NULL
Volume	NULL
(	NULL
ml	NULL
)	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

The	NULL
CD43-specific	NULL
epitope	NULL
for	NULL
mAb	NULL
J3938	NULL
is	NULL
sensitive	NULL
to	NULL
proteolysis	NULL
.	NULL

mAb	NULL
J898	NULL
antigen	NULL
was	NULL
immunoprecipitated	NULL
from	NULL
Jurkat	NULL
cells	NULL
and	NULL
treated	NULL
with	NULL
(	NULL
@	NULL
)	NULL
or	NULL
without	NULL
(	NULL
A	NULL
)	NULL
nonspecific	NULL
protease	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Glycopeptides	NULL
generated	NULL
by	NULL
proteolysis	NULL
eluted	NULL
from	NULL
the	NULL
mAb	NULL
J898-Sepharose	NULL
immunoaffinity	NULL
column	NULL
at	NULL
pH	NULL
7.5	NULL
,	NULL
predominantly	NULL
in	NULL
fractions	NULL
1-5	NULL
and	NULL
prior	NULL
to	NULL
applying	NULL
an	NULL
isocratic	NULL
shift	NULL
to	NULL
pH	NULL
8.0	NULL
.	NULL

Under	NULL
identical	NULL
conditions	NULL
,	NULL
undigested	NULL
antigen	NULL
was	NULL
retained	NULL
at	NULL
neutral	NULL
pH	NULL
and	NULL
eluted	NULL
in	NULL
fractions	NULL
5-10	NULL
following	NULL
the	NULL
isocratic	NULL
shift	NULL
to	NULL
pH	NULL
8.0	NULL
.	NULL

Chro-matographies	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
4°C	NULL
to	NULL
enhance	NULL
retention	NULL
of	NULL
low	NULL
valency	NULL
glycopeptide	NULL
.	NULL

Untreated	NULL
W6/32	NULL
+	NULL
J393	NULL
2E12	NULL
+	NULL
J393	NULL
P4C2	NULL
+	NULL
J393	NULL
G19-4	NULL
+	NULL
J393	NULL
G19-1	NULL
+	NULL
J393	NULL
PAC1O0	NULL
+	NULL
J393	NULL
60.3	NULL
+	NULL
J393	NULL
J393	NULL
0	NULL
20	NULL
_	NULL
40	NULL
60	NULL
80	NULL
%	NULL
Cell	NULL
Death	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Apoptosis	NULL
induced	NULL
by	NULL
mAb	NULL
J393	NULL
is	NULL
potentiated	NULL
by	NULL
concomitant	NULL
ligation	NULL
of	NULL
CD3/TcR	NULL
and	NULL
the	NULL
integrins	NULL
.	NULL

Actively	NULL
growing	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
5	NULL
ug/ml	NULL
mAb	NULL
J898	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
the	NULL
same	NULL
concentration	NULL
of	NULL
soluble	NULL
antibodies	NULL
directed	NULL
against	NULL
a	NULL
variety	NULL
of	NULL
surface	NULL
molecules	NULL
.	NULL

The	NULL
percent	NULL
of	NULL
cell	NULL
death	NULL
was	NULL
measured	NULL
cytofluorimetrically	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

The	NULL
mAbs	NULL
used	NULL
were	NULL
anti-CD43	NULL
(	NULL
J893	NULL
,	NULL
G19-1	NULL
)	NULL
,	NULL
anti-CD18/62-integrin	NULL
(	NULL
60.3	NULL
)	NULL
,	NULL
anti-CD29/Bl-integrin	NULL
(	NULL
P4C10	NULL
)	NULL
,	NULL
anti-CD8	NULL
(	NULL
619-4	NULL
)	NULL
,	NULL
anti-CD49d/ad-integrin	NULL
(	NULL
P4C2	NULL
)	NULL
,	NULL
anti-CD28	NULL
(	NULL
2612	NULL
)	NULL
,	NULL
and	NULL
anti-MHC	NULL
class	NULL
I	NULL
(	NULL
W6/82	NULL
)	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
none	NULL
of	NULL
the	NULL
antibodies	NULL
tested	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
mAb	NULL
J898	NULL
,	NULL
were	NULL
capable	NULL
of	NULL
inducing	NULL
apoptosis	NULL
as	NULL
soluble	NULL
,	NULL
single	NULL
reagents	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

mAbs	NULL
specific	NULL
for	NULL
either	NULL
CD3	NULL
,	NULL
CD43	NULL
,	NULL
CD18	NULL
(	NULL
B2-integrin	NULL
)	NULL
,	NULL
or	NULL
CD29	NULL
(	NULL
B1-integrin	NULL
)	NULL
increased	NULL
the	NULL
level	NULL
of	NULL
apoptosis	NULL
from	NULL
42	NULL
%	NULL
to	NULL
as	NULL
much	NULL
as	NULL
65	NULL
%	NULL
after	NULL
24	NULL
h.	NULL
Costimulation	NULL
with	NULL
either	NULL
anti-MHC	NULL
class	NULL
I	NULL
,	NULL
anti-CD28	NULL
,	NULL
or	NULL
anti-CD49d	NULL
(	NULL
«	NULL
4-integrin	NULL
)	NULL
reduced	NULL
the	NULL
level	NULL
of	NULL
apoptosis	NULL
induced	NULL
by	NULL
mAb	NULL
J393	NULL
,	NULL
demonstrating	NULL
that	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Induction	NULL
of	NULL
Apoptosis	NULL
in	NULL
T-cells	NULL
by	NULL
Anti-CD43	NULL
mAb	NULL
60	NULL
50	NULL
-I	NULL
40	NULL
30	NULL
%	NULL
Cell	NULL
Death	NULL
20	NULL
10	NULL
100	NULL
%	NULL
Cell	NULL
Death	NULL
20	NULL
T	NULL
T	NULL
0.1	NULL
1	NULL
10	NULL
100	NULL
mAb	NULL
J393	NULL
,	NULL
ug/ml	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Concomitant	NULL
ligation	NULL
of	NULL
J393/CD43	NULL
with	NULL
either	NULL
G10-2/	NULL
CD43	NULL
or	NULL
CD3/TcR	NULL
synergized	NULL
to	NULL
induce	NULL
cell	NULL
death	NULL
.	NULL

Actively	NULL
growing	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
varying	NULL
concentrations	NULL
of	NULL
mAb	NULL
J893	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
@	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
10	NULL
ug/ml	NULL
anti-CD48/mAb	NULL
G10-2	NULL
(	NULL
4	NULL
)	NULL
(	NULL
&	NULL
)	NULL
or	NULL
10	NULL
ug/ml	NULL
anti-CD3/mAb	NULL
G19-4	NULL
(	NULL
B	NULL
)	NULL
(	NULL
#	NULL
)	NULL
to	NULL
induce	NULL
apoptosis	NULL
.	NULL

The	NULL
percent	NULL
of	NULL
cell	NULL
death	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Under	NULL
these	NULL
conditions	NULL
mAb	NULL
G10-2	NULL
and	NULL
mAb	NULL
G19-4	NULL
induced	NULL
cell	NULL
death	NULL
<	NULL
5	NULL
%	NULL
when	NULL
used	NULL
as	NULL
soluble	NULL
,	NULL
single	NULL
reagents	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

only	NULL
certain	NULL
surface	NULL
molecules	NULL
interact	NULL
to	NULL
potentiate	NULL
J393/	NULL
CD43	NULL
signaling	NULL
events	NULL
.	NULL

A	NULL
synergistic	NULL
enhancement	NULL
in	NULL
cell	NULL
killing	NULL
was	NULL
observed	NULL
at	NULL
suboptimal	NULL
concentrations	NULL
of	NULL
mAb	NULL
J393	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CD43	NULL
mAb	NULL
G10-2	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
or	NULL
anti-CD3	NULL
mAb	NULL
G19-4	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Apoptosis	NULL
was	NULL
enhanced	NULL
over	NULL
2-fold	NULL
by	NULL
the	NULL
simultaneous	NULL
ligation	NULL
of	NULL
both	NULL
isoforms	NULL
of	NULL
CD43	NULL
expressed	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
the	NULL
greatest	NULL
killing	NULL
was	NULL
observed	NULL
by	NULL
the	NULL
simultaneous	NULL
ligation	NULL
of	NULL
J393/CD43	NULL
and	NULL
CD3/TcR	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
10	NULL
%	NULL
of	NULL
the	NULL
cell	NULL
population	NULL
were	NULL
killed	NULL
with	NULL
0.9	NULL
ug/ml	NULL
mAb	NULL
J393	NULL
;	NULL
however	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
soluble	NULL
anti-CD3	NULL
mAb	NULL
this	NULL
same	NULL
concentration	NULL
of	NULL
mAb	NULL
J393	NULL
induced	NULL
60	NULL
%	NULL
killing	NULL
,	NULL
a	NULL
6-fold	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
apoptosis	NULL
.	NULL

To	NULL
address	NULL
whether	NULL
the	NULL
costimulation	NULL
responsible	NULL
for	NULL
the	NULL
increase	NULL
in	NULL
apoptosis	NULL
was	NULL
due	NULL
to	NULL
the	NULL
activation-induced	NULL
production	NULL
of	NULL
the	NULL
ligand	NULL
for	NULL
CD95/Fas	NULL
(	NULL
53	NULL
)	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
costimulated	NULL
with	NULL
mAb	NULL
J393	NULL
and	NULL
mAb	NULL
G19-4	NULL
(	NULL
anti-CD3	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
antibodies	NULL
that	NULL
block	NULL
CD95/Fas-induced	NULL
apoptosis	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
soluble	NULL
CD95/Fas-Ig	NULL
fusion	NULL
protein	NULL
.	NULL

Neither	NULL
CD95/Fas	NULL
blocking	NULL
antibodies	NULL
nor	NULL
CD95/Fas-Ig	NULL
affected	NULL
the	NULL
synergistic	NULL
killing	NULL
observed	NULL
with	NULL
costimulation	NULL
of	NULL
CD43/CD3	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

mAb	NULL
J393/CD43-Induced	NULL
Protein	NULL
Tyrosine	NULL
Phosphoryl-ation-Protein	NULL
tyrosine	NULL
phosphorylation	NULL
plays	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
the	NULL
signal	NULL
transduction	NULL
pathways	NULL
of	NULL
several	NULL
T-cell	NULL
surface	NULL
molecules	NULL
including	NULL
the	NULL
CD3/TcR	NULL
,	NULL
CD4	NULL
,	NULL
CD8	NULL
,	NULL
and	NULL
CD28	NULL
(	NULL
54	NULL
)	NULL
.	NULL

27691	NULL
Untd	NULL
_	NULL
J393	NULL
G19.4sFv	NULL
-	NULL
J393	NULL
+	NULL
G19.4sFv	NULL
I	NULL
--	NULL
--	NULL
-1	NULL
Mp	NULL
pog	NULL
59s	NULL
ao	NULL
1519	NULL
30°	NULL
1	NULL
5915	NULL
30	NULL
(	NULL
kD	NULL
)	NULL
200	NULL
way	NULL
mos	NULL
Wed	NULL
«	NULL
+	NULL
H	NULL
97	NULL
-o-	NULL
=S	NULL
#	NULL
g	NULL
#	NULL
B	NULL
_	NULL
foe	NULL
'	NULL
.	NULL
'	NULL

r	NULL
«	NULL
»	NULL
an	NULL
as	NULL
an	NULL
l	NULL
’	NULL
.	NULL
'	NULL

46	NULL
#	NULL
4	NULL
bn	NULL
w	NULL
OB	NULL
©	NULL
Coz	NULL
30	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Concomitant	NULL
ligation	NULL
of	NULL
J393/CD43	NULL
and	NULL
CD3/TcR	NULL
synergized	NULL
to	NULL
increase	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
at	NULL
37	NULL
°C	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
in	NULL
minutes	NULL
with	NULL
either	NULL
5	NULL
ug/ml	NULL
anti-CD48/mAb	NULL
J898	NULL
,	NULL
10	NULL
ug/ml	NULL
anti-CD3/G19-4-sFv	NULL
fusion	NULL
protein	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
both	NULL
reagents	NULL
.	NULL

Changes	NULL
in	NULL
the	NULL
pattern	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
were	NULL
examined	NULL
by	NULL
immunoblotting	NULL
anti-phosphotyrosine	NULL
immunoprecipitates	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

In	NULL
the	NULL
above	NULL
phosphotyrosine	NULL
immunoblot	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
phosphorylated	NULL
substrates	NULL
differed	NULL
for	NULL
each	NULL
treatment	NULL
.	NULL

Although	NULL
CD43	NULL
does	NULL
not	NULL
possess	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
or	NULL
contain	NULL
tyrosine	NULL
phosphorylation	NULL
sites	NULL
within	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
(	NULL
20	NULL
)	NULL
,	NULL
its	NULL
association	NULL
with	NULL
other	NULL
membrane	NULL
receptor-tyrosine	NULL
kinase	NULL
complexes	NULL
such	NULL
as	NULL
CD3/TcR	NULL
have	NULL
been	NULL
reported	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
examined	NULL
early	NULL
tyrosine	NULL
phosphorylation	NULL
following	NULL
mAb	NULL
J393	NULL
or	NULL
mAb	NULL
J393	NULL
plus	NULL
anti-CD3	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
mAb	NULL
J393	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
anti-CD3	NULL
single-chain	NULL
variable	NULL
fragment	NULL
,	NULL
G19-4-sFv	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Following	NULL
costimulation	NULL
,	NULL
anti-phosphotyrosine	NULL
immunoprecipitates	NULL
were	NULL
analyzed	NULL
by	NULL
immunoblotting	NULL
with	NULL
anti-phosphotyrosine	NULL
antibodies	NULL
.	NULL

The	NULL
immunoblot	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
shows	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
induced	NULL
rapidly	NULL
within	NULL
1	NULL
min	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
phosphorylation	NULL
observed	NULL
depended	NULL
on	NULL
the	NULL
type	NULL
of	NULL
stimulus	NULL
.	NULL

The	NULL
most	NULL
significant	NULL
increase	NULL
in	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
induced	NULL
by	NULL
mAb	NULL
J393	NULL
was	NULL
found	NULL
in	NULL
the	NULL
range	NULL
of	NULL
90-kDa	NULL
and	NULL
below	NULL
;	NULL
in	NULL
particular	NULL
those	NULL
in	NULL
the	NULL
range	NULL
50	NULL
to	NULL
34-kDa	NULL
.	NULL

By	NULL
comparison	NULL
,	NULL
G19-4-sFv-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
proteins	NULL
above	NULL
100-kDa	NULL
as	NULL
well	NULL
as	NULL
those	NULL
below	NULL
90-kDa	NULL
but	NULL
did	NULL
not	NULL
induce	NULL
phosphorylation	NULL
of	NULL
proteins	NULL
in	NULL
the	NULL
range	NULL
of	NULL
50-55-kDa	NULL
range	NULL
.	NULL

Costimulation	NULL
with	NULL
both	NULL
antibodies	NULL
resulted	NULL
in	NULL
the	NULL
hyperphosphorylation	NULL
of	NULL
multiple	NULL
substrates	NULL
in	NULL
the	NULL
range	NULL
of	NULL
150	NULL
to	NULL
34-kDa	NULL
range	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
neither	NULL
G10-2	NULL
nor	NULL
619-1	NULL
induced	NULL
an	NULL
increase	NULL
in	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
TJ393/CD43-induced	NULL
Apoptosis	NULL
by	NULL
Phosphotyrosine	NULL
Kinase	NULL
Inhibitors-It	NULL
was	NULL
apparent	NULL
that	NULL
mAb	NULL
J393-induced	NULL
tyrosine	NULL
phosphorylation	NULL
peaked	NULL
at	NULL
5	NULL
min	NULL
and	NULL
rapidly	NULL
diminished	NULL
thereafter	NULL
.	NULL

Since	NULL
the	NULL
dephosphorylation	NULL
of	NULL
specific	NULL
substrates	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
down-regulat-ing	NULL
CD43-induced	NULL
signals	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
tyrosine	NULL
phosphatase	NULL
inhibition	NULL
on	NULL
mAb	NULL
J393-induced	NULL
apoptosis	NULL
.	NULL

Jurkat	NULL
cells	NULL
pretreated	NULL
overnight	NULL
with	NULL
the	NULL
phosphotyrosine	NULL
phosphatase	NULL
(	NULL
PTPase	NULL
)	NULL
inhibitor	NULL
,	NULL
BMLOV	NULL
(	NULL
55	NULL
)	NULL
,	NULL
were	NULL
found	NULL
to	NULL
be	NULL
more	NULL
responsive	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
mAb	NULL
J393	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8A	NULL
,	NULL
BMLOV	NULL
was	NULL
not	NULL
toxic	NULL
to	NULL
Jurkat	NULL
cells	NULL
;	NULL
however	NULL
,	NULL
it	NULL
enhanced	NULL
mAb	NULL
J393-induced	NULL
killing	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

The	NULL
level	NULL
of	NULL
cell	NULL
death	NULL
increased	NULL
from	NULL
32	NULL
to	NULL
65	NULL
%	NULL
as	NULL
a	NULL
result	NULL
of	NULL
treatment	NULL
with	NULL
45	NULL
um	NULL
BMLOV	NULL
.	NULL

Inhibition	NULL
of	NULL
PTPase	NULL
activity	NULL
by	NULL
BMLOV	NULL
had	NULL
less	NULL
effect	NULL
on	NULL
anti-CD3-induced	NULL
apoptosis	NULL
,	NULL
whether	NULL
used	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
mAb	NULL
J393	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
inhibition	NULL
of	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
on	NULL
apoptosis	NULL
was	NULL
also	NULL
examined	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

8B	NULL
,	NULL
the	NULL
level	NULL
of	NULL
apoptosis	NULL
induced	NULL
by	NULL
mAb	NULL
J393	NULL
was	NULL
reduced	NULL
from	NULL
35	NULL
to	NULL
16	NULL
%	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
27692	NULL
80	NULL
A	NULL
60	NULL
<	NULL
d	NULL
A	NULL
2	NULL
40	NULL
``	NULL
C	NULL
O	NULL
x	NULL
20	NULL
a-	NULL
-4	NULL
&	NULL
--	NULL
--	NULL
--	NULL
®	NULL
0	NULL
T	NULL
T	NULL
T	NULL
T	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
BMLOV	NULL
,	NULL
LM	NULL
B	NULL
Untreated	NULL
619-4	NULL
Herbimycin	NULL
A	NULL
J393	NULL
4393	NULL
+	NULL
Herbimycin	NULL
A	NULL
1393	NULL
+	NULL
619-4	NULL
J393	NULL
+	NULL
G19-4	NULL
+	NULL
Herbimycin	NULL
A	NULL
0	NULL
20	NULL
40	NULL
680	NULL
80	NULL
100	NULL
%	NULL
Cell	NULL
Death	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

Modulating	NULL
the	NULL
level	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
modulates	NULL
the	NULL
level	NULL
of	NULL
mAb	NULL
J398-induced	NULL
apoptosis	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
5	NULL
pg/ml	NULL
anti-CD48/mAb	NULL
J898	NULL
and	NULL
10	NULL
ug/ml	NULL
anti-CD8/mAb	NULL
G19-4	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
varying	NULL
doses	NULL
of	NULL
the	NULL
PTPase	NULL
inhibitor	NULL
BMLOV	NULL
following	NULL
an	NULL
overnight	NULL
pretreatment	NULL
with	NULL
the	NULL
inhibitor	NULL
.	NULL

The	NULL
level	NULL
of	NULL
apoptosis	NULL
was	NULL
determined	NULL
cytofluorimetrically	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

BMLOV	NULL
treatment	NULL
alone	NULL
(	NULL
@	NULL
--	NULL
@	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
mAb	NULL
G19-4	NULL
(	NULL
M	NULL
--	NULL
R	NULL
)	NULL
had	NULL
minimal	NULL
effect	NULL
on	NULL
apoptosis	NULL
;	NULL
however	NULL
,	NULL
BMLOV	NULL
acted	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
to	NULL
enhance	NULL
cell	NULL
death	NULL
induced	NULL
by	NULL
mAb	NULL
J898	NULL
(	NULL
&	NULL
-¥	NULL
)	NULL
or	NULL
mAb	NULL
J398	NULL
+	NULL
mAb	NULL
G19-4	NULL
(	NULL
@	NULL
--	NULL
@	NULL
)	NULL
.	NULL

B	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
5	NULL
ug/ml	NULL
mAb	NULL
J398	NULL
and	NULL
10	NULL
ug/ml	NULL
G19-4	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
3	NULL
uM	NULL
of	NULL
the	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
following	NULL
a	NULL
6-h	NULL
pretreatment	NULL
with	NULL
the	NULL
inhibitor	NULL
.	NULL

Herbimycin	NULL
A	NULL
treatment	NULL
alone	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
apoptosis	NULL
;	NULL
however	NULL
,	NULL
herbimycin	NULL
A	NULL
acted	NULL
to	NULL
decrease	NULL
the	NULL
level	NULL
of	NULL
cell	NULL
death	NULL
induced	NULL
by	NULL
mAb	NULL
J398	NULL
or	NULL
mAb	NULL
J398	NULL
+	NULL
mAb	NULL
G19-4	NULL
.	NULL

tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
.	NULL

Furthermore	NULL
,	NULL
apoptosis	NULL
induced	NULL
by	NULL
treating	NULL
Jurkat	NULL
cells	NULL
with	NULL
mAb	NULL
J393	NULL
plus	NULL
anti-CD3	NULL
was	NULL
inhibited	NULL
95	NULL
%	NULL
by	NULL
herbimycin	NULL
A	NULL
.	NULL

These	NULL
results	NULL
strongly	NULL
suggested	NULL
a	NULL
role	NULL
for	NULL
protein	NULL
tyrosine	NULL
phosphorylation/	NULL
dephosphorylation	NULL
events	NULL
in	NULL
regulating	NULL
CD43-mediated	NULL
signals	NULL
leading	NULL
to	NULL
an	NULL
apoptotic	NULL
response	NULL
.	NULL

mAb	NULL
J393-induced	NULL
Alterations	NULL
in	NULL
the	NULL
Nuclear	NULL
Localization	NULL
of	NULL
Transcriptional	NULL
Regulatory	NULL
Proteins-In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
mAb	NULL
J393-induced	NULL
signal	NULL
transduction	NULL
events	NULL
might	NULL
lead	NULL
to	NULL
downstream	NULL
alterations	NULL
in	NULL
gene	NULL
activation	NULL
,	NULL
we	NULL
exam	NULL
ined	NULL
the	NULL
effects	NULL
of	NULL
anti-CD43	NULL
mAb	NULL
J393	NULL
,	NULL
anti-CD3	NULL
mAb	NULL
G19-4	NULL
,	NULL
Induction	NULL
of	NULL
Apoptosis	NULL
in	NULL
T-cells	NULL
by	NULL
Anti-CD43	NULL
mAb	NULL
Untreated	NULL
G19.4	NULL
1393	NULL
G19.4	NULL
+	NULL
1393	NULL
I	NULL
E	NULL
<	NULL
-NF-	NULL
KB	NULL
hand	NULL
lung	NULL
lang	NULL
bet	NULL
<	NULL
-AP-1	NULL
l—JUHH	NULL
-Oct	NULL
tad	NULL
band	NULL
«	NULL
=	NULL
--	NULL
IRE	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

Apoptosis	NULL
induced	NULL
by	NULL
mAb	NULL
J393	NULL
is	NULL
associated	NULL
with	NULL
alterations	NULL
in	NULL
the	NULL
nuclear	NULL
localization	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
IRE	NULL
transcription	NULL
factors	NULL
.	NULL

Actively	NULL
growing	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
5	NULL
ug/ml	NULL
anti-CD48/mAb	NULL
J893	NULL
,	NULL
10	NULL
pg/ml	NULL
antiCD3/mAb	NULL
G19-4	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
two	NULL
antibodies	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
used	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
specific	NULL
DNA-binding	NULL
proteins	NULL
by	NULL
electrophoretic	NULL
gel	NULL
mobility	NULL
shift	NULL
assay	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

The	NULL
above	NULL
phosphorimages	NULL
of	NULL
non-denaturing	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
show	NULL
the	NULL
high	NULL
M	NULL
,	NULL
shift	NULL
in	NULL
radiolabel	NULL
due	NULL
to	NULL
binding	NULL
of	NULL
specific	NULL
``	NULL
°P-labeled	NULL
oligonucleotides	NULL
to	NULL
nuclear	NULL
proteins	NULL
.	NULL

Treatment	NULL
by	NULL
mAb	NULL
J898	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
mAb	NULL
G19-4	NULL
resulted	NULL
in	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
NF-kB	NULL
and	NULL
IRE	NULL
in	NULL
the	NULL
nucleus	NULL
but	NULL
did	NULL
not	NULL
affect	NULL
AP-1	NULL
or	NULL
Oct	NULL
levels	NULL
.	NULL

and	NULL
a	NULL
combination	NULL
of	NULL
both	NULL
antibodies	NULL
on	NULL
the	NULL
nuclear	NULL
localization	NULL
of	NULL
the	NULL
transcriptional	NULL
factors	NULL
NF-kB	NULL
,	NULL
AP-1	NULL
(	NULL
fos/jun	NULL
)	NULL
,	NULL
octa-mer	NULL
,	NULL
and	NULL
interferon-inducible	NULL
regulatory	NULL
element	NULL
(	NULL
IRE	NULL
)	NULL
DNA-binding	NULL
proteins	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
aliquoted	NULL
in	NULL
1-ml	NULL
volumes	NULL
containing	NULL
either	NULL
mAb	NULL
619-4	NULL
(	NULL
anti-CD3	NULL
)	NULL
,	NULL
mAb	NULL
J393	NULL
(	NULL
anti-CD43	NULL
)	NULL
,	NULL
each	NULL
at	NULL
10	NULL
ug/ml	NULL
,	NULL
a	NULL
combination	NULL
of	NULL
both	NULL
,	NULL
or	NULL
left	NULL
untreated	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
incubated	NULL
at	NULL
37	NULL
°C	NULL
for	NULL
1	NULL
h	NULL
and	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
,	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
for	NULL
analysis	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
BMS-2	NULL
cells	NULL
had	NULL
constitutively	NULL
elevated	NULL
levels	NULL
of	NULL
the	NULL
four	NULL
transcription	NULL
factors	NULL
within	NULL
the	NULL
nucleus	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
mAb	NULL
J393	NULL
had	NULL
a	NULL
marked	NULL
effect	NULL
on	NULL
reducing	NULL
the	NULL
nuclear	NULL
levels	NULL
of	NULL
both	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
IRE	NULL
binding	NULL
proteins	NULL
but	NULL
not	NULL
AP-1	NULL
or	NULL
Octamer	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
mAb	NULL
G19-4	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
nuclear	NULL
levels	NULL
of	NULL
these	NULL
factors	NULL
,	NULL
whereas	NULL
combined	NULL
antibody	NULL
treatment	NULL
inhibited	NULL
nuclear	NULL
localization	NULL
the	NULL
greatest	NULL
degree	NULL
.	NULL

Expression	NULL
of	NULL
mAb	NULL
J393	NULL
Epitopes	NULL
in	NULL
T-lymphocytes-Using	NULL
flow	NULL
cytometry	NULL
we	NULL
examined	NULL
several	NULL
different	NULL
cell	NULL
types	NULL
of	NULL
hematopoietic	NULL
origin	NULL
and	NULL
found	NULL
the	NULL
expression	NULL
of	NULL
J393/CD43	NULL
to	NULL
be	NULL
highly	NULL
restricted	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
lineages	NULL
known	NULL
to	NULL
express	NULL
CD43	NULL
were	NULL
reactive	NULL
with	NULL
mAb	NULL
G10-2	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
mAb	NULL
J393	NULL
failed	NULL
to	NULL
react	NULL
with	NULL
human	NULL
erythrocytes	NULL
,	NULL
platelets	NULL
,	NULL
neu-trophils	NULL
,	NULL
eosinophils	NULL
,	NULL
monocytes	NULL
,	NULL
T-	NULL
and	NULL
B-lymphocytes	NULL
,	NULL
freshly	NULL
isolated	NULL
CD34	NULL
``	NULL
bone	NULL
marrow-derived	NULL
precursor	NULL
cells	NULL
,	NULL
and	NULL
freshly	NULL
prepared	NULL
thymocytes	NULL
.	NULL

However	NULL
,	NULL
immunoblot	NULL
analysis	NULL
of	NULL
whole	NULL
cell	NULL
lysates	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
mAb	NULL
J393	NULL
epitopes	NULL
in	NULL
both	NULL
resting	NULL
and	NULL
activated	NULL
peripheral	NULL
blood	NULL
T-lymphocytes	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

10	NULL
,	NULL
resting	NULL
T-cells	NULL
predominantly	NULL
expressed	NULL
the	NULL
120-kDa	NULL
mAb	NULL
G10-2-reactive	NULL
isoform	NULL
of	NULL
CD43	NULL
that	NULL
appeared	NULL
to	NULL
decrease	NULL
following	NULL
cellular	NULL
activation	NULL
.	NULL

By	NULL
comparison	NULL
,	NULL
resting	NULL
T-cells	NULL
expressed	NULL
a	NULL
very	NULL
low	NULL
level	NULL
of	NULL
mAb	NULL
J893	NULL
reactivity	NULL
that	NULL
was	NULL
elevated	NULL
following	NULL
activation	NULL
.	NULL

The	NULL
140-kDa	NULL
isoform	NULL
observed	NULL
in	NULL
Jurkat	NULL
cells	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
either	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Induction	NULL
of	NULL
Apoptosis	NULL
in	NULL
T-cells	NULL
by	NULL
Anti-CD43	NULL
mAb	NULL
G10-2	NULL
J393	NULL
F	NULL
--	NULL
-	NULL
P1	NULL
p	NULL
1	NULL
2	NULL
30	NULL
40506	NULL
200	NULL
<	NULL
M	NULL
;	NULL
160	NULL
fue	NULL
<	NULL
M	NULL
,	NULL
140	NULL
dash	NULL
«	NULL
«	NULL
97	NULL
-	NULL
«	NULL
s	NULL
.	NULL

69	NULL
Fig	NULL
.	NULL

10	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
mAb	NULL
J393/CD43	NULL
epitope	NULL
in	NULL
peripheral	NULL
blood	NULL
T-cells	NULL
.	NULL

Enriched	NULL
preparations	NULL
of	NULL
peripheral	NULL
blood	NULL
T-cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
activated	NULL
for	NULL
48	NULL
h	NULL
by	NULL
costimulation	NULL
using	NULL
anti-CD3/anti-CD28	NULL
antibodies	NULL
,	NULL
and	NULL
whole	NULL
cell	NULL
lysates	NULL
were	NULL
analyzed	NULL
by	NULL
immunoblot	NULL
technique	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

mAb	NULL
G10-2	NULL
immunoblot	NULL
:	NULL
lane	NULL
1	NULL
,	NULL
Jurkat	NULL
cells	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
resting	NULL
T-cells	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
activated	NULL
T-cells	NULL
.	NULL

mAb	NULL
J898	NULL
immunoblot	NULL
:	NULL
lane	NULL
4	NULL
,	NULL
Jurkat	NULL
cells	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
resting	NULL
T-cells	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
activated	NULL
T-cells	NULL
.	NULL

As	NULL
shown	NULL
,	NULL
mAb	NULL
G10-2	NULL
lost	NULL
reactivity	NULL
with	NULL
Jurkat	NULL
cell-derived	NULL
CD43	NULL
in	NULL
Nonidet	NULL
P-40	NULL
containing	NULL
lysis	NULL
buffer	NULL
.	NULL

resting	NULL
or	NULL
activated	NULL
T-lymphocytes	NULL
;	NULL
however	NULL
,	NULL
a	NULL
higher	NULL
160-kDa	NULL
band	NULL
of	NULL
reactivity	NULL
specific	NULL
for	NULL
mAb	NULL
J393	NULL
was	NULL
present	NULL
in	NULL
activated	NULL
cells	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
in	NULL
activated	NULL
T-cells	NULL
mAb	NULL
J393	NULL
and	NULL
mAb	NULL
G10-2	NULL
cross-reacted	NULL
with	NULL
isoforms	NULL
of	NULL
CD43	NULL
that	NULL
were	NULL
of	NULL
97	NULL
kDa	NULL
or	NULL
smaller	NULL
.	NULL

As	NULL
a	NULL
further	NULL
demonstration	NULL
of	NULL
mAb	NULL
J393	NULL
reactivity	NULL
with	NULL
human	NULL
T-lymphocytes	NULL
,	NULL
PHA-activated	NULL
peripheral	NULL
T-cells	NULL
were	NULL
fixed	NULL
,	NULL
permeabilized	NULL
,	NULL
and	NULL
immunostained	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

Examination	NULL
of	NULL
this	NULL
preparation	NULL
by	NULL
confocal	NULL
microscopy	NULL
revealed	NULL
localization	NULL
of	NULL
mAb	NULL
J393	NULL
antigen	NULL
at	NULL
or	NULL
near	NULL
the	NULL
plasma	NULL
membrane	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
existence	NULL
of	NULL
a	NULL
CD43-mediated	NULL
pathway	NULL
for	NULL
signaling	NULL
apoptosis	NULL
in	NULL
T-cell	NULL
lineages	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
described	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
the	NULL
BMS-2	NULL
Jurkat	NULL
cell	NULL
line	NULL
co-expressed	NULL
two	NULL
antigenically	NULL
distinct	NULL
isoforms	NULL
of	NULL
CD43	NULL
on	NULL
its	NULL
surface	NULL
provided	NULL
us	NULL
with	NULL
a	NULL
good	NULL
model	NULL
for	NULL
examining	NULL
structure-function	NULL
relationships	NULL
between	NULL
these	NULL
two	NULL
molecules	NULL
.	NULL

While	NULL
both	NULL
mAb	NULL
J393	NULL
and	NULL
mAb	NULL
G10-2	NULL
induced	NULL
homotypic	NULL
adhesion	NULL
,	NULL
only	NULL
mAb	NULL
J393	NULL
induced	NULL
apoptosis	NULL
.	NULL

This	NULL
implied	NULL
that	NULL
the	NULL
apoptotic	NULL
response	NULL
was	NULL
independent	NULL
of	NULL
the	NULL
homotypic	NULL
adhesion	NULL
phenomenon	NULL
and	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
specific	NULL
CD43	NULL
isoform	NULL
.	NULL

The	NULL
reactivity	NULL
of	NULL
mAb	NULL
G10-2	NULL
required	NULL
terminal	NULL
sialic	NULL
acid	NULL
moieties	NULL
,	NULL
whereas	NULL
reactivity	NULL
of	NULL
mAb	NULL
J893	NULL
was	NULL
sialic	NULL
acid-independent	NULL
.	NULL

Other	NULL
investigators	NULL
have	NULL
observed	NULL
sialic	NULL
acid-independent	NULL
CD43	NULL
antibodies	NULL
to	NULL
elicit	NULL
stronger	NULL
cellular	NULL
responses	NULL
than	NULL
their	NULL
sialic	NULL
acid-dependent	NULL
counterparts	NULL
(	NULL
10	NULL
)	NULL
.	NULL

We	NULL
found	NULL
the	NULL
carbohydrate	NULL
structure	NULL
of	NULL
J393/CD43	NULL
in	NULL
Jurkat	NULL
cells	NULL
to	NULL
be	NULL
deficient	NULL
in	NULL
oligosaccharide	NULL
complexity	NULL
and	NULL
sialic	NULL
acid	NULL
content	NULL
when	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
the	NULL
G10-2/CD43	NULL
isoform	NULL
expressed	NULL
in	NULL
HPB-ALL	NULL
cells	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
serine/threonine	NULL
residues	NULL
in	NULL
the	NULL
extracellular	NULL
portion	NULL
of	NULL
the	NULL
J393	NULL
antigen	NULL
contained	NULL
only	NULL
terminal	NULL
GaINAc	NULL
monosaccharides	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
Tn	NULL
antigen-bear-ing	NULL
CD43	NULL
molecule	NULL
expressed	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Glycopeptides	NULL
generated	NULL
from	NULL
intact	NULL
mAb	NULL
J393	NULL
antigen	NULL
lost	NULL
functional	NULL
epitope	NULL
as	NULL
determined	NULL
by	NULL
immunoaffinity	NULL
chromatography	NULL
run	NULL
under	NULL
conditions	NULL
that	NULL
favor	NULL
interaction	NULL
of	NULL
low	NULL
valency	NULL
glycopeptides	NULL
with	NULL
the	NULL
antibody	NULL
.	NULL

Low	NULL
valency	NULL
for	NULL
antibodies	NULL
has	NULL
been	NULL
reported	NULL
for	NULL
glycopeptides	NULL
containing	NULL
the	NULL
cluster	NULL
antigens	NULL
of	NULL
Tn	NULL
when	NULL
compared	NULL
with	NULL
intact	NULL
glycoprotein	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Although	NULL
mAb	NULL
J393	NULL
likely	NULL
recognizes	NULL
the	NULL
T	NULL
'	NULL
n-containing	NULL
isoform	NULL
of	NULL
CD43	NULL
,	NULL
it	NULL
does	NULL
not	NULL
react	NULL
with	NULL
the	NULL
surface	NULL
of	NULL
certain	NULL
cell	NULL
types	NULL
expressing	NULL
Tn	NULL
epitopes	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
propose	NULL
that	NULL
mAb	NULL
J893	NULL
recognizes	NULL
a	NULL
unique	NULL
epitope	NULL
on	NULL
CD43	NULL
that	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
characterized	NULL
.	NULL

Fig	NULL
.	NULL

11	NULL
.	NULL

Detection	NULL
of	NULL
mAb	NULL
J393/CD43	NULL
epitopes	NULL
in	NULL
peripheral	NULL
blood	NULL
T-cells	NULL
.	NULL

Enriched	NULL
preparations	NULL
of	NULL
PHA-activated	NULL
peripheral	NULL
blood	NULL
T-cells	NULL
were	NULL
fixed	NULL
,	NULL
permeabilized	NULL
,	NULL
immunostained	NULL
with	NULL
mAb	NULL
J398	NULL
,	NULL
and	NULL
examined	NULL
by	NULL
confocal	NULL
microscopy	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

This	NULL
confocal	NULL
micrograph	NULL
depicts	NULL
the	NULL
intracellular	NULL
localization	NULL
of	NULL
mAb	NULL
J898	NULL
epitopes	NULL
in	NULL
T-cells	NULL
.	NULL

Little	NULL
is	NULL
known	NULL
about	NULL
how	NULL
CD43	NULL
functions	NULL
as	NULL
a	NULL
signaling	NULL
molecule	NULL
.	NULL

We	NULL
find	NULL
that	NULL
soluble	NULL
,	NULL
bivalent	NULL
antibody	NULL
is	NULL
sufficient	NULL
to	NULL
initiate	NULL
a	NULL
CD43	NULL
signal	NULL
,	NULL
unlike	NULL
the	NULL
requirement	NULL
for	NULL
trimeric	NULL
ligation	NULL
by	NULL
members	NULL
of	NULL
the	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
including	NULL
CD95/Fas	NULL
(	NULL
57	NULL
)	NULL
.	NULL

In	NULL
T-lymphocytes	NULL
,	NULL
CD43	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
constitutively	NULL
phosphorylated	NULL
in	NULL
resting	NULL
cells	NULL
and	NULL
hyperphosphorylated	NULL
following	NULL
cellular	NULL
activation	NULL
(	NULL
58	NULL
)	NULL
.	NULL

Because	NULL
CD43	NULL
contains	NULL
no	NULL
catalytic	NULL
region	NULL
or	NULL
tyrosine	NULL
residues	NULL
within	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
,	NULL
its	NULL
phosphorylation	NULL
is	NULL
thought	NULL
to	NULL
reflect	NULL
its	NULL
association	NULL
with	NULL
serine/threonine-specific	NULL
protein	NULL
kinases	NULL
(	NULL
59-61	NULL
)	NULL
.	NULL

However	NULL
,	NULL
investigators	NULL
characterizing	NULL
CD43	NULL
as	NULL
a	NULL
CD28-independent	NULL
costimulatory	NULL
molecule	NULL
have	NULL
described	NULL
the	NULL
physical	NULL
association	NULL
of	NULL
CD43	NULL
with	NULL
CD3	NULL
in	NULL
a	NULL
complex	NULL
containing	NULL
the	NULL
SRC	NULL
family	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
Ick	NULL
and	NULL
fyn	NULL
(	NULL
11	NULL
)	NULL
,	NULL
suggesting	NULL
an	NULL
involvement	NULL
of	NULL
CD43	NULL
with	NULL
tyrosine	NULL
phosphorylation	NULL
events	NULL
.	NULL

Indeed	NULL
,	NULL
pretreatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
significantly	NULL
interfered	NULL
with	NULL
mAb	NULL
J393-induced	NULL
cell	NULL
death	NULL
.	NULL

We	NULL
found	NULL
that	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
with	NULL
mAb	NULL
J393	NULL
induced	NULL
a	NULL
rapid	NULL
increase	NULL
in	NULL
overall	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
,	NULL
in	NULL
particular	NULL
,	NULL
for	NULL
proteins	NULL
in	NULL
the	NULL
50-55-kDa	NULL
range	NULL
.	NULL

Interestingly	NULL
,	NULL
this	NULL
group	NULL
of	NULL
proteins	NULL
was	NULL
not	NULL
phosphorylated	NULL
following	NULL
engagement	NULL
of	NULL
CD3/	NULL
TcR	NULL
,	NULL
suggesting	NULL
a	NULL
degree	NULL
of	NULL
specificity	NULL
in	NULL
the	NULL
pattern	NULL
of	NULL
CD43-induced	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

Moreover	NULL
,	NULL
concomitant	NULL
ligation	NULL
of	NULL
J393/CD43	NULL
and	NULL
CD3/TcR	NULL
resulted	NULL
in	NULL
the	NULL
hyperphosphorylation	NULL
of	NULL
these	NULL
CD43-dependent	NULL
substrates	NULL
,	NULL
providing	NULL
a	NULL
biochemical	NULL
correlate	NULL
for	NULL
the	NULL
synergy	NULL
observed	NULL
for	NULL
these	NULL
two	NULL
receptor	NULL
molecules	NULL
in	NULL
mediating	NULL
apoptosis	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
specific	NULL
substrates	NULL
is	NULL
important	NULL
in	NULL
signaling	NULL
CD43-mediated	NULL
apoptosis	NULL
.	NULL

We	NULL
found	NULL
that	NULL
preventing	NULL
dephosphorylation	NULL
of	NULL
phosphoty-rosyl	NULL
residues	NULL
by	NULL
blocking	NULL
phosphatase	NULL
activity	NULL
resulted	NULL
in	NULL
a	NULL
significant	NULL
enhancement	NULL
in	NULL
mAb	NULL
J393-induced	NULL
cell	NULL
death	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
PTPase	NULL
inhibitor	NULL
BMLOV	NULL
mimicked	NULL
the	NULL
action	NULL
of	NULL
CD3/TcR	NULL
in	NULL
potentiating	NULL
CD43-mediated	NULL
cell	NULL
death	NULL
,	NULL
seemingly	NULL
consistent	NULL
with	NULL
a	NULL
hyperphosphorylated	NULL
state	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
catalytic	NULL
activity	NULL
of	NULL
BMLOV-sensitive	NULL
phos-	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
27694	NULL
phatases	NULL
negatively	NULL
regulates	NULL
CD43-mediated	NULL
apoptosis	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
potentiation	NULL
of	NULL
CD43-mediated	NULL
apoptosis	NULL
by	NULL
CD3/IcR	NULL
engagement	NULL
involves	NULL
CD45	NULL
phosphatase	NULL
activity	NULL
since	NULL
CD45	NULL
is	NULL
expressed	NULL
in	NULL
high	NULL
abundance	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
is	NULL
required	NULL
to	NULL
activate	NULL
TcR-associated	NULL
SRC	NULL
family	NULL
kinases	NULL
allowing	NULL
for	NULL
competent	NULL
antigen-induced	NULL
signal	NULL
transduction	NULL
(	NULL
62	NULL
,	NULL
63	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
this	NULL
context	NULL
CD45	NULL
may	NULL
be	NULL
positively	NULL
regulating	NULL
CD43-mediated	NULL
apoptosis	NULL
by	NULL
directly	NULL
enhancing	NULL
kinase	NULL
activity	NULL
.	NULL

Notably	NULL
,	NULL
BMLOV	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
TcR-induced	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
55	NULL
)	NULL
which	NULL
may	NULL
explain	NULL
why	NULL
BMLOV	NULL
treatment	NULL
did	NULL
not	NULL
block	NULL
the	NULL
synergism	NULL
we	NULL
observed	NULL
for	NULL
TcR/CD43-induced	NULL
apoptosis	NULL
.	NULL

Con-versely	NULL
,	NULL
the	NULL
catalytic	NULL
activity	NULL
of	NULL
SH2	NULL
PTPases	NULL
may	NULL
be	NULL
expected	NULL
to	NULL
exert	NULL
a	NULL
negative	NULL
regulatory	NULL
effect	NULL
on	NULL
CD43-mediated	NULL
apoptosis	NULL
,	NULL
since	NULL
PTPIC	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
negatively	NULL
regulate	NULL
antigen	NULL
receptor	NULL
signaling	NULL
in	NULL
B-lymphocytes	NULL
as	NULL
confirmed	NULL
in	NULL
PTP1C-deficient	NULL
mice	NULL
expressing	NULL
the	NULL
motheaten	NULL
phenotype	NULL
(	NULL
64	NULL
)	NULL
.	NULL

Further	NULL
investigation	NULL
is	NULL
necessary	NULL
to	NULL
identify	NULL
which	NULL
enzymes	NULL
and	NULL
substrate	NULL
sites	NULL
are	NULL
involved	NULL
in	NULL
this	NULL
CD43-mediated	NULL
pathway	NULL
.	NULL

It	NULL
was	NULL
recently	NULL
reported	NULL
that	NULL
CD3/TcR-induced	NULL
apoptosis	NULL
in	NULL
T-cells	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
autocrine	NULL
production	NULL
of	NULL
the	NULL
ligand	NULL
for	NULL
CD95/Fas	NULL
(	NULL
FasL	NULL
)	NULL
,	NULL
thereby	NULL
activating	NULL
the	NULL
CD95/Fas	NULL
receptor	NULL
signaling	NULL
pathway	NULL
(	NULL
65	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
requirement	NULL
for	NULL
tyrosine	NULL
kinase	NULL
activation	NULL
in	NULL
CD95/Fas-mediated	NULL
programmed	NULL
cell	NULL
death	NULL
has	NULL
been	NULL
described	NULL
in	NULL
conjunction	NULL
with	NULL
a	NULL
requirement	NULL
for	NULL
ceramide-initiated	NULL
RAS	NULL
activation	NULL
(	NULL
66	NULL
,	NULL
67	NULL
)	NULL
;	NULL
however	NULL
,	NULL
these	NULL
signals	NULL
alone	NULL
were	NULL
not	NULL
sufficient	NULL
for	NULL
subsequent	NULL
apoptosis	NULL
.	NULL

We	NULL
found	NULL
that	NULL
neither	NULL
a	NULL
blocking	NULL
antibody	NULL
to	NULL
CD95/Fas	NULL
nor	NULL
the	NULL
competing	NULL
fusion	NULL
protein	NULL
CD95/Fas-Ig	NULL
prevented	NULL
J393/CD43-induced	NULL
apoptosis	NULL
,	NULL
making	NULL
it	NULL
unlikely	NULL
that	NULL
FasL	NULL
was	NULL
mediating	NULL
this	NULL
response	NULL
.	NULL

Moreover	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
combined	NULL
engagement	NULL
of	NULL
J393/CD43-CD3/TcR	NULL
leads	NULL
to	NULL
a	NULL
rapid	NULL
reduction	NULL
in	NULL
the	NULL
nuclear	NULL
localization	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
IRE	NULL
regulatory	NULL
proteins	NULL
normally	NULL
associated	NULL
with	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
FasL	NULL
gene	NULL
(	NULL
68	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
since	NULL
sphingomyelinase-dependent	NULL
NF-kB	NULL
activation	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
lead	NULL
to	NULL
apoptosis	NULL
signaled	NULL
by	NULL
the	NULL
TNF	NULL
receptor-1	NULL
``	NULL
death	NULL
domain	NULL
``	NULL
(	NULL
69	NULL
)	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
TNF	NULL
receptor-1	NULL
is	NULL
involved	NULL
in	NULL
J393/CD43-mediated	NULL
killing	NULL
.	NULL

Therefore	NULL
,	NULL
engagement	NULL
of	NULL
CD43	NULL
may	NULL
define	NULL
a	NULL
distinct	NULL
signaling	NULL
pathway	NULL
for	NULL
programmed	NULL
cell	NULL
death	NULL
that	NULL
differs	NULL
from	NULL
that	NULL
of	NULL
the	NULL
TNF-nerve	NULL
growth	NULL
factor	NULL
receptor	NULL
family	NULL
.	NULL

Perhaps	NULL
in	NULL
the	NULL
BMS-2	NULL
Jurkat	NULL
cells	NULL
,	NULL
constitutive	NULL
activation	NULL
and	NULL
nuclear	NULL
localization	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
IRE	NULL
DNA-binding	NULL
proteins	NULL
are	NULL
critical	NULL
for	NULL
continued	NULL
proliferation	NULL
;	NULL
hence	NULL
,	NULL
a	NULL
decrease	NULL
in	NULL
nuclear	NULL
localization	NULL
of	NULL
these	NULL
transcriptional	NULL
factors	NULL
may	NULL
lead	NULL
to	NULL
molecular	NULL
events	NULL
that	NULL
promote	NULL
growth	NULL
arrest	NULL
and	NULL
eventual	NULL
suicide	NULL
.	NULL

Recent	NULL
findings	NULL
in	NULL
CD43-deficient	NULL
T-cells	NULL
generated	NULL
by	NULL
homolo-gous	NULL
recombination	NULL
indicate	NULL
that	NULL
CD43	NULL
acts	NULL
as	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
T-cell	NULL
activation	NULL
and	NULL
proliferation	NULL
(	NULL
8	NULL
)	NULL
,	NULL
which	NULL
may	NULL
reflect	NULL
our	NULL
observation	NULL
that	NULL
CD43	NULL
signaling	NULL
can	NULL
suppress	NULL
the	NULL
activity	NULL
of	NULL
transcriptional	NULL
regulators	NULL
of	NULL
early	NULL
T-cell	NULL
activation	NULL
genes	NULL
.	NULL

While	NULL
mAb	NULL
J393	NULL
reacted	NULL
strongly	NULL
with	NULL
Jurkat	NULL
cell	NULL
surfaces	NULL
,	NULL
it	NULL
failed	NULL
to	NULL
immunostain	NULL
the	NULL
surface	NULL
of	NULL
either	NULL
resting	NULL
or	NULL
activated	NULL
peripheral	NULL
blood	NULL
T-lymphocytes	NULL
.	NULL

However	NULL
,	NULL
immunoblot	NULL
analysis	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
several	NULL
mAb	NULL
J393-reactive	NULL
proteins	NULL
in	NULL
the	NULL
lysates	NULL
of	NULL
activated	NULL
T-cells	NULL
,	NULL
possibly	NULL
representing	NULL
intracellular	NULL
intermediates	NULL
of	NULL
CD43	NULL
in	NULL
the	NULL
process	NULL
of	NULL
O-glycan	NULL
elongation	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
activated	NULL
T-cells	NULL
both	NULL
mAb	NULL
J393	NULL
and	NULL
mAb	NULL
G10-2	NULL
cross-reacted	NULL
with	NULL
a	NULL
97-kDa	NULL
isoform	NULL
of	NULL
CD43	NULL
.	NULL

Investigators	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
isoform-specific	NULL
antibodies	NULL
may	NULL
cross-react	NULL
with	NULL
linear	NULL
protein	NULL
epitopes	NULL
on	NULL
the	NULL
deglycosylated	NULL
molecule	NULL
and	NULL
that	NULL
these	NULL
epitopes	NULL
may	NULL
be	NULL
modified	NULL
by	NULL
glycosylation	NULL
in	NULL
conferring	NULL
antigenic	NULL
specificity	NULL
(	NULL
28	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
the	NULL
antigenic	NULL
specificity	NULL
for	NULL
these	NULL
two	NULL
Induction	NULL
of	NULL
Apoptosis	NULL
in	NULL
T-cells	NULL
by	NULL
Anti-CD43	NULL
mAb	NULL
antibodies	NULL
developed	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
activation-induced	NULL
changes	NULL
in	NULL
the	NULL
glycosylation	NULL
of	NULL
the	NULL
core	NULL
protein	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
mAb	NULL
J393-specific	NULL
140-kDa	NULL
isoform	NULL
present	NULL
in	NULL
Jurkat	NULL
cells	NULL
was	NULL
replaced	NULL
with	NULL
a	NULL
160-kDa	NULL
isoform	NULL
in	NULL
activated	NULL
T-cells	NULL
.	NULL

Pre-sumably	NULL
,	NULL
the	NULL
J393/CD43	NULL
intermediate	NULL
in	NULL
T-lymphocytes	NULL
contains	NULL
less	NULL
sialic	NULL
acid	NULL
than	NULL
its	NULL
counterpart	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
thus	NULL
contributing	NULL
to	NULL
its	NULL
reduced	NULL
electrophoretic	NULL
mobility	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Unlike	NULL
T-cells	NULL
from	NULL
normal	NULL
individuals	NULL
,	NULL
Jurkat	NULL
cells	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
deficient	NULL
in	NULL
B1,3-galactosyltransferase	NULL
activity	NULL
,	NULL
a	NULL
key	NULL
enzyme	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
complex	NULL
O-glycan	NULL
structures	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
postulate	NULL
that	NULL
the	NULL
epitope	NULL
for	NULL
mAb	NULL
J898	NULL
is	NULL
tightly	NULL
regulated	NULL
in	NULL
T-cell	NULL
lineages	NULL
,	NULL
normally	NULL
being	NULL
masked	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
complex	NULL
carbohydrate	NULL
chains	NULL
attached	NULL
to	NULL
the	NULL
CD43	NULL
protein	NULL
.	NULL

Our	NULL
finding	NULL
that	NULL
apoptosis	NULL
can	NULL
be	NULL
induced	NULL
through	NULL
a	NULL
CD43-mediated	NULL
pathway	NULL
may	NULL
have	NULL
physiologic	NULL
significance	NULL
in	NULL
peripheral	NULL
lymphoid	NULL
tissues	NULL
such	NULL
as	NULL
the	NULL
thymus	NULL
and	NULL
lymph	NULL
nodes	NULL
,	NULL
since	NULL
the	NULL
inhibition	NULL
of	NULL
O-glycan	NULL
elongation	NULL
in	NULL
T-cells	NULL
potenti-ates	NULL
the	NULL
apoptotic	NULL
effect	NULL
of	NULL
galectin-1	NULL
,	NULL
an	NULL
endogenous	NULL
ligand	NULL
for	NULL
CD43	NULL
expressed	NULL
at	NULL
these	NULL
sites	NULL
(	NULL
70	NULL
)	NULL
.	NULL

Concomitant	NULL
engagement	NULL
of	NULL
specific	NULL
integrin	NULL
molecules	NULL
may	NULL
serve	NULL
to	NULL
modulate	NULL
CD43-induced	NULL
responses	NULL
as	NULL
our	NULL
data	NULL
suggest	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
specific	NULL
regulation	NULL
of	NULL
integrin	NULL
expression	NULL
mediated	NULL
by	NULL
CD43	NULL
as	NULL
observed	NULL
by	NULL
others	NULL
(	NULL
71	NULL
)	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
the	NULL
truncated	NULL
O-glycan	NULL
structure	NULL
of	NULL
the	NULL
J393/CD43	NULL
molecule	NULL
represents	NULL
a	NULL
molecular	NULL
phenotype	NULL
with	NULL
an	NULL
altered	NULL
affinity	NULL
or	NULL
specificity	NULL
for	NULL
natural	NULL
ligands	NULL
involved	NULL
in	NULL
cell-cell	NULL
interactions	NULL
and	NULL
that	NULL
following	NULL
its	NULL
ligation	NULL
an	NULL
apoptotic	NULL
response	NULL
may	NULL
be	NULL
triggered	NULL
in	NULL
appropriate	NULL
cell	NULL
types	NULL
.	NULL

As	NULL
mentioned	NULL
previously	NULL
,	NULL
abnormalities	NULL
in	NULL
O-glycan	NULL
biosyn-thesis	NULL
are	NULL
found	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
pathologic	NULL
conditions	NULL
involving	NULL
hematopoietic	NULL
and	NULL
immunologic	NULL
disorders	NULL
,	NULL
often	NULL
correlating	NULL
with	NULL
the	NULL
appearance	NULL
of	NULL
Tn	NULL
antigen	NULL
and	NULL
autoantibodies	NULL
to	NULL
cell-surface	NULL
molecules	NULL
including	NULL
CD43	NULL
(	NULL
14	NULL
,	NULL
18	NULL
,	NULL
72	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
alternatively	NULL
glycosylated	NULL
isoforms	NULL
of	NULL
CD43	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
progression	NULL
of	NULL
such	NULL
diseases	NULL
by	NULL
promoting	NULL
T-cell	NULL
deficiency	NULL
and	NULL
lymphopenia	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Acknowledgments-We	NULL
express	NULL
our	NULL
appreciation	NULL
to	NULL
Drs	NULL
.	NULL

Jeffrey	NULL
Ledbetter	NULL
,	NULL
Gary	NULL
Schieven	NULL
,	NULL
Paul	NULL
Gladstone	NULL
,	NULL
Jacques	NULL
Garrigues	NULL
,	NULL
and	NULL
Irv	NULL
Bernstein	NULL
(	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
reagents	NULL
,	NULL
Patti	NULL
Moran-Davis	NULL
and	NULL
Alison	NULL
Wallace	NULL
for	NULL
expert	NULL
technical	NULL
assistance	NULL
,	NULL
and	NULL
Teresa	NULL
Nelson	NULL
for	NULL
assistance	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Remold-O'Donnell	NULL
,	NULL
E.	NULL
,	NULL
Kenny	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Parkman	NULL
,	NULL
R.	NULL
,	NULL
Cairns	NULL
,	NULL
L.	NULL
,	NULL
Savage	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Rosen	NULL
,	NULL
F.	NULL
S.	NULL
(	NULL
1984	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

159	NULL
,	NULL
1705-1723	NULL
2	NULL
.	NULL

Kenny	NULL
,	NULL
D.	NULL
,	NULL
Cairns	NULL
,	NULL
L.	NULL
,	NULL
Remold-O'Donnell	NULL
,	NULL
E.	NULL
,	NULL
Peterson	NULL
,	NULL
J.	NULL
,	NULL
Rosen	NULL
,	NULL
F.	NULL
S.	NULL
,	NULL
and	NULL
Parkman	NULL
,	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Blood	NULL
68	NULL
,	NULL
1329-1332	NULL
3	NULL
.	NULL

Brown	NULL
,	NULL
W.	NULL
R.	NULL
A.	NULL
,	NULL
Barclay	NULL
,	NULL
A.	NULL
N.	NULL
,	NULL
Sunderland	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
Williams	NULL
,	NULL
A.	NULL
F.	NULL
(	NULL
1981	NULL
)	NULL
Nature	NULL
289	NULL
,	NULL
456-460	NULL
4	NULL
.	NULL

Rosenstein	NULL
,	NULL
Y.	NULL
,	NULL
Park	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Hahn	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Rosen	NULL
,	NULL
F.	NULL
S.	NULL
,	NULL
Bierer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nature	NULL
854	NULL
,	NULL
233-235	NULL
5	NULL
.	NULL

Ardman	NULL
,	NULL
B.	NULL
,	NULL
Sikorski	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Staunton	NULL
,	NULL
D.	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

89	NULL
,	NULL
5001-5005	NULL
6	NULL
.	NULL

Manjunath	NULL
,	NULL
N.	NULL
,	NULL
Johnson	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Staunton	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Pasqualini	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Ardman	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
1528-1534	NULL
.	NULL

Kojima	NULL
,	NULL
N.	NULL
,	NULL
Saito	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Shuichi	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

214	NULL
,	NULL
587-542	NULL
.	NULL

Manjunath	NULL
,	NULL
N.	NULL
,	NULL
Correa	NULL
,	NULL
M.	NULL
,	NULL
Ardman	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Ardman	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Nature	NULL
877	NULL
,	NULL
535-538	NULL
9	NULL
.	NULL

Sportsman	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Park	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Cheresh	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Fukuda	NULL
,	NULL
M.	NULL
,	NULL
Elder	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Fox	NULL
,	NULL
R.	NULL
I	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

185	NULL
,	NULL
158-164	NULL
10	NULL
.	NULL

Axelsson	NULL
,	NULL
B.	NULL
,	NULL
Youseffi-Etemad	NULL
,	NULL
R.	NULL
,	NULL
Hammarstrom	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Perlmann	NULL
,	NULL
P.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

141	NULL
,	NULL
2912-2917	NULL
11	NULL
.	NULL

Alvarado	NULL
,	NULL
M.	NULL
,	NULL
Klassen	NULL
,	NULL
C.	NULL
,	NULL
Cerny	NULL
,	NULL
J.	NULL
,	NULL
Horejsi	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Schmidt	NULL
,	NULL
R.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25	NULL
,	NULL
1051-1055	NULL
12	NULL
.	NULL

Parkman	NULL
,	NULL
R.	NULL
,	NULL
Remold-O'Donnell	NULL
,	NULL
E.	NULL
,	NULL
Kenny	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Perrine	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Rosen	NULL
,	NULL
F.	NULL
S.	NULL
(	NULL
1981	NULL
)	NULL
Lancet	NULL
ii	NULL
,	NULL
1387-1389	NULL
13	NULL
.	NULL

Siminovitch	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Greer	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
Axelsson	NULL
,	NULL
B.	NULL
,	NULL
Rubin	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Novogrodsky	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Peacocke	NULL
,	NULL
M.	NULL
(	NULL
1998	NULL
)	NULL
Immunodefic	NULL
.	NULL

Rev	NULL
.	NULL

4	NULL
,	NULL
99-108	NULL
14	NULL
.	NULL

Ardman	NULL
,	NULL
B.	NULL
,	NULL
Sikorski	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Settles	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Staunton	NULL
,	NULL
D.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1151-1158	NULL
15	NULL
.	NULL

Lefebvre	NULL
,	NULL
J.-C.	NULL
,	NULL
Giordanengo	NULL
,	NULL
V.	NULL
,	NULL
Limouse	NULL
,	NULL
M.	NULL
,	NULL
Doglio	NULL
,	NULL
A.	NULL
,	NULL
Cucchiarini	NULL
,	NULL
M.	NULL
,	NULL
Monpoux	NULL
,	NULL
F.	NULL
,	NULL
Mariani	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Peyron	NULL
,	NULL
J.-F.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
1609-1617	NULL
go	NULL
=a	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
16	NULL
.	NULL

17.	NULL
.	NULL

Thunher	NULL
,	NULL
M.	NULL
,	NULL
Rusconi	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Berger	NULL
,	NULL
E.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

91	NULL
,	NULL
19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

82	NULL
.	NULL

38	NULL
.	NULL

84	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37.	NULL
.	NULL

Hewick	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Hunkapiller	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Hood	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
and	NULL
Dryer	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

Induction	NULL
of	NULL
Apoptosis	NULL
in	NULL
T-cells	NULL
by	NULL
Anti-CD43	NULL
mAb	NULL
Ellies	NULL
,	NULL
L.	NULL
G.	NULL
,	NULL
Jones	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
Williams	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Ziltener	NULL
,	NULL
H.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Glycobi-ology	NULL
4	NULL
,	NULL
885-893	NULL
Saitoh	NULL
,	NULL
O.	NULL
,	NULL
Piller	NULL
,	NULL
F.	NULL
,	NULL
Fox	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
Fukuda	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Blood	NULL
77	NULL
,	NULL
1491-1499	NULL
2103-2110	NULL
Shelley	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Remold-O'Donnell	NULL
,	NULL
E.	NULL
,	NULL
Davis	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Bruns	NULL
,	NULL
G.	NULL
A.	NULL
P.	NULL
,	NULL
Rosen	NULL
,	NULL
F.	NULL
S.	NULL
,	NULL
Carroll	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
and	NULL
Whitehead	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

86	NULL
,	NULL
2819-2823	NULL
Pallant	NULL
,	NULL
A.	NULL
,	NULL
Eskenazi	NULL
,	NULL
A.	NULL
,	NULL
Mattei	NULL
,	NULL
M.-G.	NULL
,	NULL
Fournier	NULL
,	NULL
R.	NULL
E.	NULL
K.	NULL
,	NULL
Carlsson	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Fukuda	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Frelinger	NULL
,	NULL
J.	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

86	NULL
,	NULL
1328-1332	NULL
Shelly	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Remold-O'Donnell	NULL
,	NULL
E.	NULL
,	NULL
Rosen	NULL
,	NULL
F.	NULL
S.	NULL
,	NULL
and	NULL
Whitehead	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

270	NULL
,	NULL
569-576	NULL
Cyster	NULL
,	NULL
J.	NULL
,	NULL
Somoza	NULL
,	NULL
C.	NULL
,	NULL
Killeen	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Williams	NULL
,	NULL
A.	NULL
F.	NULL
(	NULL
1990	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

20	NULL
,	NULL
875-881	NULL
Cyster	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Shotton	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Williams	NULL
,	NULL
A.	NULL
F.	NULL
(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

10	NULL
,	NULL
893-902	NULL
Jones	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
Federsppiel	NULL
,	NULL
B.	NULL
,	NULL
Ellies	NULL
,	NULL
L.	NULL
G.	NULL
,	NULL
Williams	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Burgener	NULL
,	NULL
R.	NULL
,	NULL
Duronio	NULL
,	NULL
V.	NULL
,	NULL
Smith	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Takei	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Ziltener	NULL
,	NULL
H.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

153	NULL
,	NULL
3426-3439	NULL
Bierhuizen	NULL
,	NULL
M.	NULL
F.	NULL
A.	NULL
,	NULL
Maemura	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Fukuda	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
4473-4479	NULL
Fox	NULL
,	NULL
R.	NULL
I.	NULL
,	NULL
Hueniken	NULL
,	NULL
M.	NULL
,	NULL
Fong	NULL
,	NULL
S.	NULL
,	NULL
Behar	NULL
,	NULL
S.	NULL
,	NULL
Royston	NULL
,	NULL
I.	NULL
,	NULL
Singhal	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
L.	NULL
(	NULL
1983	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

181	NULL
,	NULL
762-767	NULL
Baum	NULL
,	NULL
L.	NULL
G.	NULL
,	NULL
Pang	NULL
,	NULL
M.	NULL
,	NULL
Perillo	NULL
,	NULL
N.	NULL
L.	NULL
,	NULL
Wu	NULL
,	NULL
T.	NULL
,	NULL
Delegeane	NULL
,	NULL
A.	NULL
,	NULL
Uittenbogarrt	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Fukuda	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Seilhamer	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
877-887	NULL
Silvermann	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
Wong	NULL
,	NULL
R.	NULL
C.	NULL
K.	NULL
,	NULL
Remold-O'Donnell	NULL
,	NULL
E.	NULL
,	NULL
Vercelli	NULL
,	NULL
D.	NULL
,	NULL
Sancho	NULL
,	NULL
J.	NULL
,	NULL
Terhorst	NULL
,	NULL
C.	NULL
,	NULL
Rosen	NULL
,	NULL
F.	NULL
,	NULL
Geha	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Chatila	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
4194-4200	NULL
Wong	NULL
,	NULL
R.	NULL
,	NULL
Remold-O'Donnell	NULL
,	NULL
E.	NULL
,	NULL
Vercelli	NULL
,	NULL
D.	NULL
,	NULL
Sancho	NULL
,	NULL
J.	NULL
,	NULL
Terhorst	NULL
,	NULL
C.	NULL
,	NULL
Rosen	NULL
,	NULL
F.	NULL
,	NULL
Geba	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Chatila	NULL
,	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
1455-1460	NULL
Mentzer	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Remold-O'Donnell	NULL
,	NULL
E.	NULL
,	NULL
Crimmis	NULL
,	NULL
M.	NULL
A.	NULL
V.	NULL
,	NULL
Bierer	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Rosen	NULL
,	NULL
F.	NULL
S.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165	NULL
,	NULL
1383-1392	NULL
Sperling	NULL
,	NULL
A.	NULL
I.	NULL
,	NULL
Green	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Mosley	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Smith	NULL
,	NULL
P.	NULL
L.	NULL
,	NULL
DiPaolo	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Klein	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182	NULL
,	NULL
139-146	NULL
Bazil	NULL
,	NULL
V.	NULL
,	NULL
Brandt	NULL
,	NULL
J.	NULL
,	NULL
Tsukamoto	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hoffman	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Blood	NULL
86	NULL
,	NULL
502-511	NULL
Cooper	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
Chase	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Lowman	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Krivit	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
Good	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1968	NULL
)	NULL
Clin	NULL
.	NULL

Stud	NULL
.	NULL

44	NULL
,	NULL
499-513	NULL
Bowen	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Lane	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
and	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1985	NULL
)	NULL
Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

108	NULL
,	NULL
704-709	NULL
Hayden	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Gayle	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Bajorath	NULL
,	NULL
J.	NULL
,	NULL
Brady	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Norris	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Fell	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Gilliland	NULL
,	NULL
L.	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Therap	NULL
.	NULL

Immunol	NULL
.	NULL

1	NULL
,	NULL
3-15	NULL
Mittler	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Greenfield	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Schacter	NULL
,	NULL
B	NULL
.	NULL

Z.	NULL
,	NULL
Richard	NULL
,	NULL
N.	NULL
F.	NULL
,	NULL
and	NULL
Hoffmann	NULL
,	NULL
M.	NULL
K.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

188	NULL
,	NULL
3159-8166	NULL
Matsudaira	NULL
,	NULL
P.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
10035-10038	NULL
Chem	NULL
.	NULL

256	NULL
,	NULL
7990-7997	NULL
Maresh	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Wang	NULL
,	NULL
W.-C.	NULL
,	NULL
Beam	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Malacko	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Hellstrom	NULL
,	NULL
L.	NULL
,	NULL
Hellstom	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
and	NULL
Marquardt	NULL
,	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
Arch	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

811	NULL
,	NULL
95-102	NULL
Lee	NULL
,	NULL
N.	NULL
,	NULL
Wang	NULL
,	NULL
W.-C.	NULL
,	NULL
and	NULL
Fukuda	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
20476-20487	NULL
41	NULL
.	NULL

42	NULL
.	NULL

48	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

TL	NULL
.	NULL

72	NULL
.	NULL

27695	NULL
Carlsson	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Sasaki	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Fukuda	NULL
,	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

261	NULL
,	NULL
12787-12795	NULL
Maemura	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Fukuda	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
24379-24386	NULL
Wang	NULL
,	NULL
W.-C.	NULL
,	NULL
Clark	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
Smith	NULL
,	NULL
D.	NULL
F.	NULL
,	NULL
and	NULL
Cummings	NULL
,	NULL
R.	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

175	NULL
,	NULL
390-896	NULL
Mittler	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Rankin	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
and	NULL
Kiener	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

147	NULL
,	NULL
3484-3440	NULL
Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebovitz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1489	NULL
Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
705-716	NULL
Tepper	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Nadler	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Esselstyn	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Sterbenz	NULL
,	NULL
K.	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

155	NULL
,	NULL
2427-2486	NULL
Mittler	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Rao	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
Talle	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Look	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Goldstein	NULL
,	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
J.	NULL
Kxp	NULL
.	NULL

Med	NULL
.	NULL

158	NULL
,	NULL
99-111	NULL
Piller	NULL
,	NULL
V.	NULL
,	NULL
Piller	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Fukuda	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
9264-9271	NULL
Nakada	NULL
,	NULL
H.	NULL
,	NULL
Inoue	NULL
,	NULL
M.	NULL
,	NULL
Tanaka	NULL
,	NULL
N.	NULL
,	NULL
Numada	NULL
,	NULL
Y.	NULL
,	NULL
Kitagawa	NULL
,	NULL
H.	NULL
,	NULL
Fukui	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Yama-Shina	NULL
,	NULL
I	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

179	NULL
,	NULL
762-767	NULL
Dakour	NULL
,	NULL
J.	NULL
,	NULL
Lundblad	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Zopf	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

161	NULL
,	NULL
140-148	NULL
Ohlson	NULL
,	NULL
S.	NULL
,	NULL
Lundblad	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Zopf	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

169	NULL
,	NULL
204-208	NULL
Dhein	NULL
,	NULL
J.	NULL
,	NULL
Walczak	NULL
,	NULL
H.	NULL
,	NULL
Baumler	NULL
,	NULL
C.	NULL
,	NULL
Debatin	NULL
,	NULL
K.-M.	NULL
,	NULL
and	NULL
Krammer	NULL
,	NULL
P.	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
878	NULL
,	NULL
488-441	NULL
Rudd	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Janssen	NULL
,	NULL
O.	NULL
,	NULL
Cai	NULL
,	NULL
Y.-C.	NULL
,	NULL
da	NULL
Silva	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Raab	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Prasad	NULL
,	NULL
K.	NULL
V.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
225-234	NULL
Schieven	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Wahl	NULL
,	NULL
A.	NULL
F.	NULL
,	NULL
Myrdal	NULL
,	NULL
S.	NULL
,	NULL
Grosmaire	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
20824-20831	NULL
Inoue	NULL
,	NULL
M.	NULL
,	NULL
Nakada	NULL
,	NULL
H.	NULL
,	NULL
Tanaka	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Yamashina	NULL
,	NULL
I	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

54	NULL
,	NULL
85-88	NULL
Smith	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Farrah	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Goodwin	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
959-962	NULL
Piller	NULL
,	NULL
V.	NULL
,	NULL
Piller	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Fukuda	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
18824-18831	NULL
Chatila	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Geha	NULL
,	NULL
R.	NULL
S.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
4308-4314	NULL
Axelsson	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Perlmann	NULL
,	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

80	NULL
,	NULL
589-547	NULL
Fukuda	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Carlsson	NULL
,	NULL
S.	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Med	NULL
.	NULL

Biol	NULL
.	NULL

64	NULL
,	NULL
335-343	NULL
Hovis	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Donovan	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Musci	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Motto	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Goldman	NULL
,	NULL
F.	NULL
D.	NULL
,	NULL
Ross	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
and	NULL
Koretzky	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Science	NULL
260	NULL
,	NULL
544-546	NULL
Volarevic	NULL
,	NULL
S.	NULL
,	NULL
Niklinska	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
,	NULL
Burns	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Weissman	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
Ashwell	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Science	NULL
260	NULL
,	NULL
541-5438	NULL
Thomas	NULL
,	NULL
M.	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
Immunology	NULL
7	NULL
,	NULL
279-288	NULL
Ju	NULL
,	NULL
S.-T.	NULL
,	NULL
Panka	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Cui	NULL
,	NULL
H.	NULL
,	NULL
Ettinger	NULL
,	NULL
R.	NULL
,	NULL
El-Khatib	NULL
,	NULL
M.	NULL
,	NULL
Sherr	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Stanger	NULL
,	NULL
B	NULL
.	NULL

Z.	NULL
,	NULL
and	NULL
Marshak-Rothstein	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Nature	NULL
878	NULL
,	NULL
444-448	NULL
Eischen	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Dick	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Leibson	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

153	NULL
,	NULL
1947-1954	NULL
Gulbins	NULL
,	NULL
E.	NULL
,	NULL
Bissonnette	NULL
,	NULL
R.	NULL
,	NULL
Mahboubi	NULL
,	NULL
A.	NULL
,	NULL
Martin	NULL
,	NULL
S.	NULL
,	NULL
Nishioka	NULL
,	NULL
W.	NULL
,	NULL
Brunner	NULL
,	NULL
T.	NULL
,	NULL
Baier	NULL
,	NULL
G.	NULL
,	NULL
Baier-Bitterlich	NULL
,	NULL
G.	NULL
,	NULL
Byrd	NULL
,	NULL
C.	NULL
,	NULL
Lang	NULL
,	NULL
F.	NULL
,	NULL
Kolesnick	NULL
,	NULL
R.	NULL
,	NULL
Altman	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Immunity	NULL
2	NULL
,	NULL
841-351	NULL
Takahashi	NULL
,	NULL
T.	NULL
,	NULL
ef	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

6	NULL
,	NULL
1567-1574	NULL
Wiegmann	NULL
,	NULL
K.	NULL
,	NULL
Schutze	NULL
,	NULL
S.	NULL
,	NULL
Machleidt	NULL
,	NULL
T.	NULL
,	NULL
Witte	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Kronke	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
78	NULL
,	NULL
1005-1015	NULL
Perillo	NULL
,	NULL
N.	NULL
L.	NULL
,	NULL
Pace	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Seilhamer	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Baum	NULL
,	NULL
L.	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
878	NULL
,	NULL
736-739	NULL
Hernandez-Caselles	NULL
,	NULL
T.	NULL
,	NULL
Martinez-Esparza	NULL
,	NULL
M.	NULL
,	NULL
Lazarovits	NULL
,	NULL
A.	NULL
I.	NULL
,	NULL
and	NULL
Aparicio	NULL
,	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
3668-3677	NULL
Berger	NULL
,	NULL
E.	NULL
G.	NULL
,	NULL
Thurnher	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Dinter	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Transfus	NULL
.	NULL

Clin	NULL
.	NULL

Biol	NULL
.	NULL

1	NULL
103-108	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
Aq	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL
Characterization	NULL
of	NULL
a	NULL
CD43/Leukosialin-mediated	NULL
Pathway	NULL
for	NULL
Inducing	NULL
Apoptosis	NULL
in	NULL
Human	NULL
T-Lymphoblastoid	NULL
Cells	NULL
T.	NULL
Joseph	NULL
Brown	NULL
,	NULL
Walt	NULL
W.	NULL
Shuford	NULL
,	NULL
Wei-Chun	NULL
Wang	NULL
,	NULL
Steven	NULL
G.	NULL
Nadler	NULL
,	NULL
Tina	NULL
S.	NULL
Bailey	NULL
,	NULL
Hans	NULL
Marquardt	NULL
and	NULL
Robert	NULL
S.	NULL
Mittler	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1996	NULL
,	NULL
271:27686-27695.	NULL
doi	NULL
:	NULL
10.1074/jb0.271.44.27686	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/271/44/27686	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
72	NULL
references	NULL
,	NULL
39	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
uo	NULL
1son	NULL
$	NULL
4q	NULL
/S10°0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wrojr	NULL
popeopumog	NULL

